Podcasts about Tandem

 It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: cancer reserach may lead to T1D treatment, GLP-1 oral pill moves forward, Tandem pharmacy moves, Medtronic-Abbott sensor unveield, parents of kids with T1D see income drop, Mannkind submits Afrezza for pediatrics, diabetes scholarships and more! Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom   Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links:   Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX Cornell researchers have developed an implant system that can treat type 1 diabetes by supplying extra oxygen to densely packed insulin-secreting cells, without the need for immunosuppression. The system could also potentially provide long-term treatment for a range of chronic diseases. This lab has produced previous implantable devices that have proved effective in controlling blood sugar in diabetic mice, but they can only last so long. "It's the proof of concept. We really proved that oxygenation is important, and oxygenation will support high cell-density capsules," Tempelman said. "The capsules are immune protective and last for a long time without having some kind of fouling of the membrane. The body never likes it when you put a foreign substance in. So that's the engineering in the Ma Lab, to look for materials and coatings for the materials that are immune protective, but also don't invoke excess response from the body because of the material." The next step will be to implant the system in a pig model, and also test it with human stem cells. The researchers are interested in eventually trying to use the system for implanting different cell types in humans for long-term treatment of chronic diseases, according to Tempelman, who is CEO of Persista Bio Inc., a new startup she founded with Ma and Flanders that is licensing these technologies. https://medicalxpress.com/news/2025-08-implant-diabetes-oxygenating-insulin-cells.html XX Mayo Clinic cancer research may be big news for T1D. After identifying a sugar molecule that cancer cells use on their surfaces to hide from the immune system, the researchers have found the same molecule may eventually help in the treatment of type 1. Cancer cells use a variety of methods to evade immune response, including coating themselves in a sugar molecule known as sialic acid. The researchers found in a preclinical model of type 1 diabetes that it's possible to dress up beta cells with the same sugar molecule, enabling the immune system to tolerate the cells. The findings show that it's possible to engineer beta cells that do not prompt an immune response   In the preclinical models, the team found that the engineered cells were 90% effective in preventing the development of type 1 diabetes. The beta cells that are typically destroyed by the immune system in type 1 diabetes were preserved.     https://newsnetwork.mayoclinic.org/discussion/mayo-clinic-researchers-find-sugar-coating-cells-can-protect-those-typically-destroyed-in-type-1-diabetes/ XX A daily pill may be as effective in lowering blood sugar and aiding weight loss in people with Type 2 diabetes as the popular injectable drugs Mounjaro and Ozempic, according to results of a clinical trial announced by Eli Lilly on Thursday morning.   The drug, orforglipron, is a GLP-1, a class of drugs that have become blockbusters because of their weight-loss effects. But the GLP-1s on the market now are expensive, must be kept refrigerated and must be injected. A pill that produces similar results has the potential to become far more widely used, though it is also expected to be expensive.   Lilly said it would seek approval from the Food and Drug Administration later this year to market orforglipron for obesity and early in 2026 for diabetes. https://www.nytimes.com/2025/04/17/health/pill-glp-1-eli-lilly.html XX Use of diabetes technology has dramatically increased and glycemic control has improved among people with type 1 diabetes (T1D) in the US over the past 15 years, but at the same time, overall achievement of an A1c level < 7% remains low and socioeconomic and racial disparities have widened. These findings came from an analysis of national electronic health records of nearly 200,000 children and adults with T1D by Michael Fang, PhD, of the Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, and colleagues. The study was published online on August 11, 2025, in JAMA Network Open. Use of continuous glucose monitors (CGMs) increased substantially from 2009-2011 to 2021-2023, from less than 5% in both children and adults to more than 80% and over half, respectively. While A1c levels did drop over the 15 years, just 1 in 5 children and slightly over a quarter of adults achieved a level < 7%. The average A1c level stayed above 8%, with ethnic minorities and low-income patients seeing the smallest gains.       https://www.medscape.com/viewarticle/diabetes-tech-use-rise-a1c-reductions-still-lag-2025a1000lc9 XX Inflammation may predict how well people with diabetes respond to depression treatment, and the effects differ dramatically between type 1 and type 2 diabetes. Diabetes and depression often appear together. Indeed, depression is more than three times more prevalent in people with type 1 diabetes (T1D) and nearly twice as prevalent in people with type 2 diabetes (T2D). When they appear together, treatment for depression can vary widely. In a new study, researchers from the German Diabetes Center (DDZ), the Research Institute of the Diabetes Academy Mergentheim (FIDAM), and the German Center for Diabetes Research (DZD) investigated how inflammation in the body relates to improvement in depression symptoms in people with T1D and T2D. The researchers combined data from three previous German randomized clinical trials that aimed to reduce elevated depressive symptoms and diabetes distress in people with type 1 or type 2 diabetes. Diabetes distress is characterized by feelings of overwhelm, frustration, guilt and worry about diabetes management and its potential complications. A total of 332 participants with T1D and 189 with T2D who had completed both a baseline and 12-month follow-up examination were included in the present study. Measures included depression using the Center for Epidemiological Studies Depression scale (CES-D), blood tests for 76 inflammatory biomarkers, and symptoms broken down into cognitive-affective (e.g., feeling hopeless), somatic (e.g., poor sleep, fatigue), and anhedonia (loss of pleasure) clusters.   After adjusting for factors like age, body mass index (BMI), diabetes duration, cholesterol, and co-existing illnesses, the researchers found that in patients with T1D, higher baseline inflammation was linked to smaller improvements in depression. Inflammation seemed to be more connected to physical/somatic symptoms in T1D patients. In those with T2D, higher baseline inflammation was linked to greater improvements in depression. For these patients, the effect was strongest for cognitive-affective and anhedonia – so, emotional and motivational – symptoms.   The researchers weren't sure what caused the difference between T1D and T2D, but they suggest it might be due to the different forms of immune activation seen in each condition. That is, autoimmune processes in type 1 and metabolic inflammation in type 2. https://newatlas.com/health-wellbeing/inflammation-diabetes-depression-treatment/ XX Parents of children diagnosed with type 1 diabetes suffer an income drop in the years following the diagnosis. The impact is more pronounced in mothers, especially mothers of children diagnosed in preschool years. And these findings come from a European study.. not the US. Previous research has shown that parents of children with type 1 diabetes are at increased risk of stress-related symptoms and may need to reduce their working hours. "In our study, we observed reduced parental work-related incomes in the years following the child's type 1 diabetes diagnosis. The drop was larger in mothers than in fathers. Since mothers earned significantly less than fathers in absolute terms, even before the child fell ill, the relative drop in mothers was 6.6% the year following diagnosis compared to 1.5% in fathers. We further note the greatest impact on work-related incomes in mothers of children diagnosed at preschool age," says Beatrice Kennedy, physician at the Endocrine and Diabetes unit at Uppsala University Hospital and Associate Professor of Medical Epidemiology at Uppsala University, who led the study. This is a huge study, builds on data from national population and health registers and the Swedish Child Diabetes Register (Swediabkids). The study includes the parents of more than 13,000 children diagnosed with type 1 diabetes in Sweden in 1993−2014, as well as more than half a million parents in the general population who have children not diagnosed with diabetes.   The researchers observed that the maternal pension-qualifying incomes (a composite outcome including work-related income and societal benefits) initially increased after the child's diagnosis. This was attributable to mothers applying for the parental care allowance from the Swedish Social Insurance Agency. The parental care allowance was intended to compensate for disease-related loss of work-related income and contribute toward disease-specific costs.   When the research team investigated long-term effects in mothers, they found that the pension-qualifying incomes gradually decreased after eight years, and had not recovered by the end of follow-up − 17 years after the children were diagnosed. https://www.news-medical.net/news/20250811/Mothers-face-greater-financial-impact-following-childe28099s-type-1-diabetes-diagnosis.aspx XX The U.S. Department of Justice has reached a settlement with Metro Nashville Public Schools after allegations that the district violated the Americans with Disabilities Act.   The parents of a student at the Ross Early Learning Center requested that the school monitor their child's glucose monitor. Investigators found the school refused to do so, despite the child's Type 1 Diabetes diagnosis.   As part of the settlement, MNPS agreed to change its policies to allow the use of these devices, ensure trained staff can monitor them throughout the entire school day and at school activities, and improve communication with parents. https://www.wsmv.com/2025/08/12/metro-nashville-public-schools-settles-allegations-it-discriminated-against-students-with-diabetes/ XX Modular Medical has unveiled Pivot, its next-generation insulin patch pump technology aimed at simplifying diabetes care. The company announced its new pump for “almost-pumpers” at the Association of Diabetes Care & Education Specialists (“ADCES”) Conference in Phoenix, Arizona this weekend. It aims for Pivot to target adults with a user-friendly, affordable design.   Modular Medical's current pump, the MODD1, won FDA clearance nearly a year ago. It features new microfluidics technology to allow for the low-cost pumping of insulin. The system has a reservoir size of 300 units/3mL. Users can monitor the pump activity with their cell phone and do not require an external controller. The pump uses a provided, single-use, disposable battery.   The company announced recently that it validated its insulin pump cartridge line for human-use production in the U.S. Days later, it reported the first human use of the MODD1 pump.   Now, it has taken the next steps with the debut of a next-gen pump, set for FDA submission in October.   Modular Medical also gamifies diabetes care The company also said ADCES is the place where it will showcase the first playable level of its new Pivot pump gamified trainin module. Level Ex, a developer of medical games, develops the module.   Modular Medical said gamification offers a way to make medical training more effective and efficient while improving information retention. Given the complexity in pump uptake, the company hopes to provide an easy way to bring its technology to clinicians and patients.   The company expects to have training modules available at the same time as the pump's planned launch in 2026.   “Level One is free because diabetes mastery shouldn't come with a price tag,” Sam Glassenberg, CEO of Level Ex, said. “Modular Medical is breaking barriers too – bringing pump therapy to more people through smart, accessible design. Together, we intend to make diabetes management simpler and more inclusive.   “People learn best through play – and we believe they want to learn about insulin pumps the same way. In Level One, players aren't just mastering diabetes management through gameplay – they're asking to ‘play' with pumps: to explore how they work, understand their benefits, and build confidence before using them in real life. Our partnership with Modular Medical helps make that possible.” https://www.drugdeliverybusiness.com/modular-medical-unveils-next-gen-insulin-pump/ XX On Tuesday, 12 August 2025, Tandem Diabetes Care (NASDAQ:TNDM) presented at the Canaccord Genuity's 45th Annual Growth Conference, outlining strategic shifts and market focus. The company highlighted its plans for commercial transformation in the U.S. and expansion in international markets, alongside addressing competitive challenges and regulatory impacts. While optimistic about growth in Outside the U.S. (OUS) markets, Tandem is navigating a more competitive landscape domestically. We have entered into the pharmacy channel with Mobi only. And so as Mobi's been building up volume, we're getting experience and we're really learning and understanding what pharmacy offers to us. And the proof points have proved out the thesis I said earlier, which is it can really reduce that barrier for patients, is the out of pocket cost. And so we've decided to accelerate our strategy and where we were starting just with Mobi, we are now moving t slim supplies into the pharmacy channel, and that will kick into gear in the fourth quarter. So as people are looking at the cadence of sales for the remainder of the year with this reframing, many folks are seeing what looks like a a might be an outsized fourth quarter and and having trouble understanding those dynamics. We'll be adding the tSIM supplies to those contracts. We also have more coverage. We will have it in the coming weeks effective this year, so we will be increasing that 30% rate before the end of the year. And then, obviously, everyone's in the same cycle right now already negotiating and discussing their 2026 coverage. And so 30% is the floor.   We do expect to continue to grow that coverage in the coming years, and ultimately have a much broader access. Absolutely. It's an exciting technology that allows for us to have an infusion set that extends the wear time from three days to up to seven days. So we're able to use that as part of an independent infusion set, which would then be used with the t slim and with the mobi pump today. But we're also using that same technology as part of the site that's used for mobi when you use it with a tubeless cartridge. So next year, we will launch Mobi in a patch configuration.   It uses the same pump that's available today, but by using a modified cartridge, you're able to wear it as a patch pump. So one of the things we announced on the call is that we're using this extended wear technology as part of that site. So what it allows you to do is to change the portion that you wear in your skin separate from the timing of when you change the insulin cartridge. So it allows for that extended wear time, reduction of burden to the patient, which is especially important for higher volume insulin users as we expand into type two. So from here, we will launch the extended wear site next year along with we'll do a separate regulatory filing for the cartridge portion for Mobi that includes this extended wear technology as a predicate device. So that's another filing that we'll need to do, but we have the clearance today for the independent infusion set, but we'll file another five ten k for use of the extended wear technology as part of the tubeless Mobi feature. https://za.investing.com/news/transcripts/tandem-diabetes-at-canaccord-conference-strategic-shifts-and-market-focus-93CH-3834464 XX MannKind today announced a significant regulatory submission and a large financing agreement with Blackstone. The company submitted its lead inhaled insulin product for expanded FDA approval and secured $500 million in funding, it said.   First, the Danbury, Connecticut-based company announced that it submitted a supplemental Biologics License Application (sBLA) for Afrezza, its inhaled insulin product, in the pediatric population.   MannKind Director of Medical and Scientific Engagement Joanne Rinker, MS, RDN, BC-ADM, CDCES, LDN, FADCES, told Drug Delivery Business News at ADA 2025 that a submission was on the way for children and adolescents aged 4-17 years old. Further data shared at ADA found Afrezza both safe and effective in that age range.   Afrezza is a fast-acting insulin formulation delivered through an inhaler device. MannKind engineered the mechanical inhaler device to slowly bring powder into the lung. A small compartment opens for the insertion of the insulin cartridge, then the user closes it. The only other component is a mouthpiece for the sake of cleanliness. Then, the inhalation takes just two seconds. It requires no electronics or extra components.   The company expects a review acceptance decision early in the fourth quarter of 2025.   “The submission of our supplemental Biologics License Application (sBLA) for Afrezza in pediatric patients is a meaningful milestone for MannKind and people living with diabetes,” said Michael Castagna, CEO of MannKind Corporation.   Additional funding provides a significant boost for MannKind MannKind also announced a strategic financing agreement with funds managed by Blackstone worth up to $500 million. The financing provides MannKind with non-dilutive capital to advance its short- and long-term growth strategies.   This senior secured credit facility includes a $75 million initial term loan funded at closing. It then has a $125 million delayed draw term loan available for the next 24 months. Finally, it features an additional $300 million uncommitted delayed draw term loan available at the mutual consent of MannKind and Blackstone.   The facility bears interest at a calculated SOFR variable rate plus 4.75% and matures in August 2030.   “This strategic financing significantly increases our operating flexibility and provides us substantial access to non-dilutive capital on favorable terms, complementing our strong cash position,” said Castagna. “The funding will support the expansion of our commercial team in preparation for the anticipated launch of the pediatric indication for Afrezza, if approved, continued pipeline advancement, potential business development opportunities, and general corporate purposes. Partnering with the Blackstone team on this transaction positions us to accelerate our next phase of growth and innovation.” https://www.drugdeliverybusiness.com/mannkind-fda-submission-pediatrics-500m-blackstone/ XX   Medtronic MiniMed Abbott Instinct Sensor [Image from Medtronic Diabetes on LinkedIn] The Medtronic Diabetes business today took to social media to share an early preview of a new integrated Abbott sensor for its insulin delivery systems. Medtronic Diabetes — soon to be MiniMed after its planned separation from the medtech giant – said in the post that the new sensor specifically designed for its own systems is called “Instinct.”   “Get a sneak peek at what's coming next: the Instinct sensor,” the business unit's account wrote. “Made by Abbott, the Instinct sensor is designed exclusively for MiniMed systems. We'll share more details about the Instinct sensor when it's commercially available.”   The sensor, built on the Abbott FreeStyle Libre platform, reflects “the power of the partnership,” Abbott EVP, Diabetes Care, Chris Scoggins, told Drug Delivery Business News earlier this year.   Medtronic and Abbott — two of the largest diabetes tech companies in the world — announced a year ago that they entered into a global partnership pairing Abbott continuous glucose monitors (CGMs) with Medtronic insulin delivery systems.   The partnership aims to collaborate on a system based on Abbott's FreeStyle Libre CGMs with Medtronic's automated insulin delivery technology (the latest generation being the MiniMed 780G) and smart insulin pen systems, such as the InPen system.   Read more about Medtronic, Abbott and the rest of the diabetes tech industry in our free Diabetes Technology Special Report. Medtronic's systems previously used its own CGMs, such as the Guardian 4 and the Simplera platform, and the company intends to continue using those systems as part of a comprehensive CGM portfolio. Under the companies' agreement, the systems would be sold exclusively by Medtronic — including the Abbott CGM.   The companies brought the partnership a step further in April when Medtronic announced the submission of an interoperable pump with the Abbott sensor technology to the FDA. They plan to share more details following the expected FDA clearance, which remains pending.   Management also recently emphasized the multi-year nature of the partnership, meaning Medtronic could pair current and future pumps with other Abbott sensors in the future. That could hint at integration with the company's future dual glucose-ketone monitor, as a number of pump makers have already announced collaborations to pair their systems with the sensor once it hits the market. https://www.drugdeliverybusiness.com/medtronic-diabetes-previews-abbott-sensor-minimed/ XX Governor Glenn Youngkin joined Civica officials at the company's Petersburg manufacturing facility to announce a $3 million grant from the Commonwealth of Virginia to accelerate Civica's efforts to develop and produce affordable insulin for Americans living with diabetes.   CivicaRx Logo   "We are proud to partner with Civica in their mission to make essential medicines more accessible," said Governor Youngkin. "This investment reflects our belief in the power of public-private collaboration to improve lives and strengthen communities."   These funds will support the production of insulin aspart, a rapid-acting human insulin analog used to regulate blood sugar in adults and children with diabetes. Civica plans to produce both rapid- and long-acting insulins at its state-of-the-art manufacturing facility in Petersburg, Va., where the company now employs more than 200 skilled workers.1 Over 8 million people living with diabetes need rapid-acting and/or long-acting insulin.   The Governor also announced that he had officially proclaimed August 7 – 14 2025 'Life Sciences Week' demonstrating the Commonwealth's commitment to "accelerating the advancement of the life sciences through public-private partnerships, STEM education, workforce development, and sustained investment in research and development."   "We are grateful for the Commonwealth's support," said Ned McCoy, Civica's President and CEO. "This funding will help us move closer toward our goal of ensuring that no one has to choose between insulin and other basic needs."   Civica and Virginia officials were joined by Lynn Starr, Chief Global Advocacy Officer of Breakthrough T1D, the leading global type 1 diabetes research and advocacy organization.   "More than one million American adults live with type 1 diabetes, and many still, sadly, ration their insulin, due to the prohibitively high cost of this necessary medication," said Starr.  "Civica's work will help to make insulin more affordable for people across the country."   Breakthrough T1D is among more than two dozen organizations and philanthropists, along with the states of Virginia and California, that have partnered with Civica to support the development of affordable insulins.   Civica's insulin initiative aims to provide patients with predictable, transparent pricing — no more than $30 per vial or $55 for a box of five pens — regardless of insurance status.   About Civica Civica is a nonprofit pharmaceutical company established to address drug shortages. It was founded by a group of U.S. health systems and philanthropies who, after more than a decade of chronic shortages, recognized that the market was not self-correcting and that a different approach is required. Civica works to deliver a safe, stable, and affordable supply of essential medicines to U.S. patients.   Media Contact: Liz Power liz.power@civicarx.org +1 860 501 3849 https://cbs4indy.com/business/press-releases/cision/20250807NY46213/governor-glenn-youngkin-announces-3-million-grant-to-support-civicas-affordable-insulin-programs/ XX If you or someone you love is living with diabetes, you already know the fight isn't just medical—it's financial, too. Between daily supplies, doctor visits, and long-term care, the cost of managing type 1 or type 2 diabetes can be overwhelming. Add college or trade school into the equation, and suddenly staying healthy competes with building a future. That's where scholarships for students with diabetes—like Beyond Scholars and others listed here—step in.   Whether you're headed to a university, a two-year college, or a hands-on trade program, these opportunities were created to ease the load.   Scholarships for students with diabetes Beyond Scholars (from Beyond Type 1): $10,000 for recently graduated high school seniors with type 1 diabetes or type 2 diabetes entering college or trade school. This is one of the largest needs-based diabetes scholarships in the United States. This year, awardees will also receive 6 months of wellness coaching through Risely Health.   Applications open: July 25, 2025 Deadline: August 29, 2025 Winners announced: October 2025 https://beyondtype1.org/beyond-scholars-diabetes-scholarships-college-trade-school/ XX Nick Jonas and Kyle Rudolph are using their platforms for a good cause.   On Tuesday, Aug. 12, the singer and the former NFL tight end (via his professional fundraising platform Alltroo) announced they're teaming up to launch a rally featuring a fan-coveted prize: a custom 2025 Volkswagen ID. Buzz electric bus that the Jonas Brothers have brought along for their 20th anniversary tour.   “Ten years ago, we hit the road with a goal to change what it means to live with diabetes. Since then, Beyond Type 1 has grown into the world's largest digital diabetes community, offering the tools, education, and peer support needed to not only survive but thrive with diabetes,” Jonas, who co-founded Beyond Type 1 (a nonprofit that advocates for those living with diabetes), says in a statement.     “We've challenged stigma, built community, provided life-saving resources, and collectively driven global innovation toward prevention and cure. This milestone is a moment to rally even more support for our mission, and partnering with Alltroo helps us do that in a powerful, engaging way.”   Related Stories Nick Jonas on Managing His Diabetes: 'The Mental and Emotional Health Aspect Is Really Important' nick jonas Nick Jonas Says He Was Diagnosed with Diabetes After Joe Told Their Parents: 'Something's Really Wrong' Joe Jonas and Nick Jonas attend the amfAR Cannes Gala 30th edition at Hotel du Cap-Eden-Roc on May 23, 2024 For Rudolph, the campaign is about "celebrating Beyond Type 1's incredible work over the past decade, and standing behind their vision of a world where everyone with diabetes — or at risk of it — has access to the knowledge, care and support needed for early diagnosis and lifelong health."   While the rally is live on Alltroo.com, fans can also scan QR codes available at all 36 Jonas Brothers concert stops to enter for a chance to win the electric bus. (A winner will be selected on November 14, which is World Diabetes Day.)   Jonas, 32, has long been open about his Type 1 diabetes diagnosis at 13 years old. "I had this kind of wrench thrown into things when I was diagnosed and it took a while to figure out how to count carbs to properly dose for insulin and what things would affect me in different ways," he previously told PEOPLE.   "When I was first diagnosed, I was sitting in the hospital and was scared to death, honestly, while I was learning about how to manage this new thing I was dealing with," Jonas recalled. "It would have been amazing to have someone to look at at that time to say, oh, this is a person living with it and they're following their dreams. They're doing what they want to do with their lives and not letting it slow them down."           https://people.com/nick-jonas-kyle-rudolph-launch-fan-rally-diabetes-awareness-11788684

When brand and product are treated as separate silos, user trust suffers. In this episode, Focus Lab CEO Bill Kenney and Max Q Co-Founder Lee Eisenbarth unpack what it means to build software experiences that feel cohesive—because they are.They explore how design systems, microcopy, onboarding flows, and even 404 pages can carry the weight of brand, not as decoration, but as the soul of the experience. You'll hear examples from companies like Slack, Linear, and Ledger, and leave with tactics to align product with purpose — even on a lean budget.Key Takeaways:Why brand-product misalignment kills trust (and how to fix it)Where to inject brand personality into the product — without overdoing itSmall but mighty ways to make technical UX feel humanHow internal teams (not just marketing) scale brand consistentlyWhether you're building your MVP or scaling a platform, this is your playbook for embedding brand into every corner of your product.Episode Resources:Learn more about MaxQ"Brand Isn't the Frosting. It's the Framework." (Article by Lee Eisenbarth)Connect with Lee on LinkedInPrint Magazine / Headspace Brand ArticleFocus Lab is an established B2B brand agency that believes, without question, that the most successful companies are the ones who invest in branding. Focus Lab creates transformative B2B brands that resonate with their customers and stand out as industry leaders. Through a proven process and a shared commitment to create unforgettable experiences, we develop true partnerships that help B2B brands become their boldest, most original selves.STAY IN TOUCH:Newsletter: https://focuslab.agency/subscribeLinkedIn: https://www.linkedin.com/company/focus-lab-llcInstagram: @focuslabllc Looking for a brand agency? We would love to hear from you. Email us: hello@focuslab.agency

Imagine cycling from Lands End to John O'Groats...on a folding bike! Well Listener Bobby Reading who has just set off to do exactly that.  JBobby's family sadly lost three grandparents in the space of just a few weeks and he is using the ride as a fundraiser for Care Rights UK. Follow Bobby via his instagram account - @bigbobsadventures and you can donate to his fundraiser here. We also hear from Tom and Gavin from @BlindlyCycling about being the first pair to attempt the Transcontinental Race on a Tandem bike.Watch my video all about Spectating at the Tour de France here.RedWhite Apparel - Check out the most comfortable bib shorts on the market! Support the showBuy me a coffee and help support the show! I'm an affiliate for a few brands I genuinely use and recommend including:

Tandem est une tragicomédie française réalisée par Patrice Leconte, sortie en 1987. Lʹhistoire dʹune épopée radiophonique. Lʹhistoire de deux hommes, liés par le travail, lʹamitié, la servitude, lʹhabitude. Lʹhistoire dʹun jeu, de la campagne française, de la route, des bourgeois imbus dʹeux-mêmes, des beaufs, des questions avec réponses et des questions sans réponses. Tandem, est un road-movie écrit par Patrice Leconte, inspiré de la carrière de lʹanimateur radio Lucien Jeunesse et du jeu des mille francs. A lʹécran, Jean Rochefort incarne un animateur un peu ringard et dépassé, vieux beau flamboyant, Mortez, et Gérard Jugnot, Rivetot, son ingénieur du son, homme à tout faire, est son souffre-douleur et valet. Les deux hommes ne peuvent exister lʹun sans lʹautre. Ils sont un Tandem qui sillonne la France jusquʹà la déchéance de Mortez. Film subtil, où le malaise se glisse discrètement dans les dialogues, dans les situations rencontrées sur la route, ou pendant le jeu radiophonique, Tandem fait basculer Patrice Leconte dans la cour des grands cinéastes. En 1987, alors quʹon classe le réalisateur des Bronzés parmi les amuseurs publics, le voilà qui surprend tout le monde par la dimension dramatique de son film, par le côté Don Quichotte et Sancho Panza des personnages. Il faut dire aussi que ses comédiens sont exceptionnels : Jean Rochefort en zazou décati, véritable cabotin, et Gérard Jugnot que personne nʹattendait dans ce rôle tout en retenue et en émotion. Gérard Jugnot qui, pour lʹoccasion, se rase la moustache et porte une perruque pour cacher sa calvitie. Un nouveau physique qui le fait sʹévader du rôle de petit gros franchouillard et montre lʹétendue de son talent. Aujourdʹhui, dans Travelling, nous prenons la route avec Patrice Leconte et son Tandem de comédiens. Nous avons retrouvé beaucoup dʹarchives maison sur ce film. Nous les écouterons. Nous avons également comme source la biographie de Patrice Leconte, Je suis un imposteur, parue chez Flammarion. Dès lors, ne tardons plus. Ce nʹest pas le jeu de La langue au chat qui nous occupera, mais bien un émission radiophonique sur ce Tandem magnifique. REFERENCES Patrice Leconte, J'arrête le cinéma, Calmann-Lévy, 2011. Yves Alion (dir.) et Patrice Leconte, Tandem, un film de Patrice Leconte : découpage intégral et dialogues, Alice Éditions, coll. " L'Avant-scène Cinéma " (no 673), mai 2020 Patrice Leconte, Je suis un imposteur, Flammarion Tandem, bonus making-of https://www.allocine.fr/video/player_gen_cmedia=19589811&cfilm=2587.html Jugnot sur Tandem https://www.ina.fr/ina-eclaire-actu/video/bxc8707012335/cinema-interview-de-gerard-jugnot-au-sujet-du-film-tandem

In this conversation, Jared Prevost shares his journey into the real estate industry, discussing his initial interest sparked by a YouTube video and his subsequent experiences in wholesaling, flipping, and lending. He emphasizes the importance of building a sustainable business model and the advantages of midterm rentals. Jared also talks about his software company, Tandem, which supports real estate coaching, and his strategies for investing in properties across different markets. Professional Real Estate Investors - How we can help you: Investor Fuel Mastermind:  Learn more about the Investor Fuel Mastermind, including 100% deal financing, massive discounts from vendors and sponsors you're already using, our world class community of over 150 members, and SO much more here: http://www.investorfuel.com/apply   Investor Machine Marketing Partnership:  Are you looking for consistent, high quality lead generation? Investor Machine is America's #1 lead generation service professional investors. Investor Machine provides true ‘white glove' support to help you build the perfect marketing plan, then we'll execute it for you…talking and working together on an ongoing basis to help you hit YOUR goals! Learn more here: http://www.investormachine.com   Coaching with Mike Hambright:  Interested in 1 on 1 coaching with Mike Hambright? Mike coaches entrepreneurs looking to level up, build coaching or service based businesses (Mike runs multiple 7 and 8 figure a year businesses), building a coaching program and more. Learn more here: https://investorfuel.com/coachingwithmike   Attend a Vacation/Mastermind Retreat with Mike Hambright: Interested in joining a “mini-mastermind” with Mike and his private clients on an upcoming “Retreat”, either at locations like Cabo San Lucas, Napa, Park City ski trip, Yellowstone, or even at Mike's East Texas “Big H Ranch”? Learn more here: http://www.investorfuel.com/retreat   Property Insurance: Join the largest and most investor friendly property insurance provider in 2 minutes. Free to join, and insure all your flips and rentals within minutes! There is NO easier insurance provider on the planet (turn insurance on or off in 1 minute without talking to anyone!), and there's no 15-30% agent mark up through this platform!  Register here: https://myinvestorinsurance.com/   New Real Estate Investors - How we can work together: Investor Fuel Club (Coaching and Deal Partner Community): Looking to kickstart your real estate investing career? Join our one of a kind Coaching Community, Investor Fuel Club, where you'll get trained by some of the best real estate investors in America, and partner with them on deals! You don't need $ for deals…we'll partner with you and hold your hand along the way! Learn More here: http://www.investorfuel.com/club   —--------------------

Vancouver Canucks fans have high hopes in their goalie tandem of Thatcher Demko and Kevin Lankinen. I talk about how well it stacks up against the rest of the Canadian teams, the rest of the Pacific Division, and the rest of the league.

In this heartfelt and deeply insightful episode, Laura shares the stories of her four very different births — unfolding under different models of care and each offering her profound lessons in motherhood, birth and self-trust.Laura's journey begins in the public hospital system, where despite a positive first birth experience with her son Harry, she reflects on the loss of her mother during this pivotal time and how little guidance she felt she had as a new parent throughout pregnancy and postpartum. Her second birth with Arthur ended in a caesarean that she still questions the necessity of. She reflects on the disconnect from her body during this experience and speaks of Arthur's postpartum period which brought unexpected challenges, including a long battle with oral and breast thrush which she conquered and continued to breastfeed throughout.It was during her third pregnancy, in the midst of COVID and a chance encounter with a doula, that Laura found a path to empowered, supported birth. With her daughter Yasmine, she experienced a healing homebirth VBAC, surrounded by care providers who respected her body and her choices. Her fourth and final birth — a planned homebirth with her daughter Freya — was another transformative experience, this time with all three of her children present, a birth photographer and a doula, highlighting the beauty of including family and additional supports in the birthing space.Laura speaks with honesty, wisdom, and reverence for her body's journey — from navigating grief and fragmented care to discovering the power of continuity, community, and bodily autonomy. She reflects on tandem feeding, her husband's evolving role in the birth space and how these birth experiences shaped her parenting and worldview.This is an episode rich with insights into informed decision-making, birth choices in Australia, breastfeeding difficulties and the value of trusting yourself through every stage of motherhood.Please join us on our journey to bringing you all kinds of VBAC stories from across the country from here on in by subscribing and following us on social media, @australianvbacstories on Instagram and Australian VBAC Stories on Facebook. Laura shares a resource, 'Beyond the sling' by Mayim Bialik, which can be found here. If you enjoyed this episode, we'd love to rate or review, and tell your friends!If you are feeling that you might benefit from mental health support after listening to our podcast, please reach out to one of the organisations below:PANDA ⁠⁠⁠⁠⁠⁠https://panda.org.au/⁠⁠⁠⁠⁠⁠Gidget Foundation ⁠⁠⁠⁠⁠⁠https://www.gidgetfoundation.org.au/⁠⁠⁠⁠⁠⁠COPE Australia ⁠⁠⁠⁠⁠⁠https://www.cope.org.au/⁠⁠⁠⁠⁠⁠If you've experienced mistreatment or disrespectful care in your pregnancy, birth or postpartum and are seeking advocacy support, please contact one of the following organisations:Maternity Choices Australia ⁠⁠⁠⁠⁠⁠https://www.maternitychoices.org/⁠⁠⁠⁠⁠⁠Maternity Consumer Network ⁠⁠⁠⁠⁠⁠https://www.maternityconsumernetwork.org.au/⁠⁠⁠⁠⁠⁠Thank you for tuning in to our podcast.

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: FDA approves the first fast-acting biosimilar insulin in the US, Tandem issues warning, DOJ stands up for remote monitoring in schools, GLP1 use protects against dementia, and more! Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom   Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links:   Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX We've got the first and only biosimilar FDA approved and moving to market. Kirsty – insulin aspart, which is a biosimilar to Novolog will be available as a single-patient-use prefilled pen for subcutaneous use and a multiple-dose vial for subcutaneous and intravenous use. KIRSTY has been available in Europe and Canada since 2022. This same company makes Semglee, the first biosimilar for long acting? Sales of Insulin Aspart in the United States were approximately $1.9 billion in 2024, according to IQVIA. https://www.globenewswire.com/news-release/2025/07/15/3115973/0/en/Biocon-Biologics-Expands-Diabetes-Portfolio-with-FDA-Approval-of-Kirsty-the-First-and-Only-Interchangeable-Rapid-Acting-Insulin-Aspart-in-the-United-States.html XX Tandem Diabetes Care (Nasdaq:TNDM) has issued an urgent medical device correction for some t:slim X2 automated insulin pumps. In a July 22 notice, the San Diego-based company warned of pumps that may exhibit a higher rate of speaker failure. During normal use, the insulin pump software monitors current flowing through the speaker during use. Measurements that fall within a pre-determined range indicate a functioning speaker. Meanwhile, measurements falling outside the range indicate a speaker failure.   When the measurements land outside the expected range, the system declares a malfunction, referred to as “Malfunction 16.” If the pump declares this malfunction, insulin delivery will stop and the pump will no longer be operational. Malfunction 16 terminates communication between the pump and continuous glucose monitor (CGM), as well as the t:slim mobile app.   If not addressed, the issue can lead to hyperglycemia, which can result in hospitalization or medical intervention. The company reports 700 adverse events and 59 reported injuries to date, with no reports of death.   Tandem identified that certain speaker versions have a higher rate of Malfunction 16 events due to a wiring issue within the speaker. Users can continue using their pump but with added precautions because Malfunction 16 can occur at any time. They should use the t:slim mobile app with push notifications turned on so the app alerts them if the malfunction occurs, the company said.   Additionally, Tandem intends to release a software update aimed at enhancing the early detection of speaker failure. The update also introduces persistent vibration alarms to help reduce potential safety risk. Tandem plans to notify affected pump users when it makes the update available. https://www.drugdeliverybusiness.com/tandem-warns-insulin-pump-speaker-malfunction/ XX BIG WIN! The DOJ protects T1D rights again! The US Attorney's office for the Western District of Washington State reached a settlement with a public school district that once again confirms remotely monitoring students' CGMs is a reasonable accommodation that schools must provide to comply with the Americans with Disabilities Act. If its true for one state its true for all states under federal law! If your local schools still refuse to remotely monitor CGMs of their students, provide them with this letter to compel them to FOLLOWT1Ds and FOLLOW Federal Laws. If they still refuse contact us! https://followt1ds.org/ XX new study finds people taking GLP-1 agonists had a significantly lower cumulative risk of developing dementia, when compared to metformin users. Past studies show that people who have type 2 diabetes — a chronic condition where the body does not use its insulin properly — are at a higher risk of developing dementia. The study found that when comparing the neuroprotective abilities of two diabetes medications — metformin and glucagon-like peptide-1 receptor agonists (GLP-1 agonists) — participants taking GLP-1 agonists had a significantly lower cumulative risk of developing dementia, when compared to metformin.   https://www.medicalnewstoday.com/articles/glp-1s-may-offer-better-dementia-protection-than-metformin XX Front office changes coming to Dexcom.  CEO Kevin Sayer will step down  & give the reins to current Chief Operating Officer Jake Leach. Scheduled for January 1, 2026, Leach will also join Dexcom's board of directors where Sayer will remain  executive chairman. One of our frequent guests here.. Leach has worked at Dexcom for 21 years. He served as chief technology officer from 2018 to 2022 before he was named COO in late 2022. He was given the title of president in May. https://www.medtechdive.com/news/dexcom-ceo-change-kevin-sayer-jake-leach/756382/ XX A major international study has revealed that many children and young adults in Sub-Saharan Africa who are diagnosed with type 1 diabetes (T1D) may actually have a different, non-immune-based form of the condition. Unlike the traditional autoimmune version of T1D, this form appears to develop without the immune system attacking the insulin-producing cells. This finding could significantly reshape how diabetes is diagnosed and treated across the region, potentially leading to more precise care and better health outcomes. The researchers found that many young people in Sub-Saharan Africa diagnosed with T1D often don't have the usual markers in their blood (called islet autoantibodies) typically seen in people with T1D in other parts of the world. Specifically, 65% of participants with T1D in this region did not have islet autoantibodies. When the researchers compared this data to studies in the U.S., they found a smaller but significant proportion (15%) of Black participants diagnosed with T1D had a similar form of diabetes found in Sub-Saharan Africa – characterized by negative autoantibodies and a low T1D genetic risk score.   However, white Americans with T1D showed the typical autoimmune pattern, even if they didn't have detectable autoantibodies, their genetics still pointed to autoimmune diabetes.   “The identification of this T1D diabetes subtype in Sub-Saharan African populations and among individuals of African ancestry in the U.S. suggests a potential ancestral or genetic link,” Dabelea notes. “These findings highlight the need to consider alternative etiologies in this group and a deeper understanding of the underlying mechanisms may provide important insights for future prevention and treatment strategies.”     https://scitechdaily.com/new-diabetes-subtype-discovered-in-africa-challenges-global-assumptions/   XX Formal recognition for the specialty of Diabetology.   Diabetology is the specialty focused on the full continuum of diabetes care — encompassing diagnosis, treatment, prevention, technology integration, education, and cardiometabolic management. While it intersects with endocrinology, primary care, and public health, diabetology is uniquely defined by its depth and focus on diabetes alone.       The American College of Diabetology (ACD) is the national professional organization representing clinicians who specialize in diabetes care. ACD advances clinical excellence and education to improve the lives of those affected by diabetes. https://www.businesswire.com/news/home/20250725766248/en/American-College-of-Diabetology-Announces-Formal-Taxonomy-Classification-for-Diabetology   XX Tidepool announces cloud-to-cloud integration with Abbott's FreeStyle Libre portfolio. From the release: This integration allows people living with diabetes using the FreeStyle Libre portfolio to connect their data to their Tidepool account seamlessly. For healthcare providers, this means more comprehensive insights and streamlined workflows, with FreeStyle Libre systems data flowing continuously into the Tidepool Data Platform. https://www.tidepool.org/blog/abbott-freestyle-libre-integration-launched XX Stelo dexom ai food XX With high drug prices remaining an ongoing concern for U.S. politicians, Roche is considering following in the footsteps of some of its peers with a direct-to-consumer (DTC) model to cut out the middlemen.     About 50% of the money spent on drugs in the U.S. healthcare system goes straight to PBMs instead of the companies that create the medicines, Roche CEO Thomas Schinecker called out in a press conference on Thursday.   Bringing the drugs directly to the consumer could be a solution to positively impact pricing for patients “without destroying innovation,” Schinecker added on a separate Thursday call with investors, noting that the company has discussed the matter with the U.S. government and its Department of Health and Human Services. The pricing talks come after President Donald Trump inked a “Most Favored Nation” executive order in May, aiming to tie U.S. drug prices to lower prices in other developed nations. The plan was quickly called out by industry voices such as the PhRMA trade group, which labeled it a “bad deal” for U.S. patients. https://www.fiercepharma.com/pharma/roche-weighing-direct-consumer-drug-sales-ease-us-drug-pricing-woes-cut-out-pbms-ceo-says XX SAB BIO secures substantial $175M financing to advance T1D therapy with impressive investor lineup and extended cash runway until 2028. Most critically, this financing fully funds the pivotal Phase 2b SAFEGUARD study evaluating SAB-142 for delaying progression of autoimmune Type 1 diabetes in newly diagnosed patients. By extending the cash runway into mid-2028, SAB has effectively eliminated near-term financing risk and provided clear visibility through this crucial clinical trial and potential commercialization preparation. Participation from strategic investor Sanofi, along with new investors RA Capital Management, Commodore Capital, Vivo Capital, Blackstone Multi-Asset Investing, Spruce Street Capital, Forge Life Science Partners and Woodline Partners LP, and existing investors Sessa Capital, the T1D Fund, and ATW Partners         https://www.stocktitan.net/news/SABS/sab-bio-announces-oversubscribed-175-million-private-fwsf2t91ek4z.html   XX In a landmark 14-year study, researchers have found that artificially sweetened drinks raise the risk of developing type 2 diabetes by more than a third, significantly higher than those loaded with sugar. It challenges the long-standing perception of diet drinks being a healthier alternative and suggests they may carry metabolic risks of their own. In the first longitudinal study of its kind, led by Monash University, researchers tracked 36,608 participants over an average period of 13.9 years to assess how both sugar-sweetened beverages (SSBs) and artificially sweetened beverages (ASBs) impacted health outcomes. The self-reported health data, from the Melbourne Collaborative Cohort Study, was drawn from participants aged 40 to 69 years at the time of recruitment.   What they found was that drinking just one can of artificially sweetened soda increased the risk of developing type 2 diabetes by 38%, compared to people who didn't consume these drinks at all. For those consuming the same amount of sugary drinks, the risk was 23% higher. This suggests there's more than obesity at play. The researchers believe this result is due to an independent metabolic effect, possibly gut microbiome disruption or a change in glucose metabolism.   While the study didn't identify which artificial sweeteners were at play,   Evidence suggests that artificial sweeteners can alter the composition and function of gut bacteria, leading to glucose intolerance – a precursor to type 2 diabetes. And that some sweeteners may trigger insulin release, desensitize metabolic responses over time, or confuse the body's glucose regulation system – even without actual sugar in the picture.   Another hypothesis is that regular exposure to the kind of intense sweetness that artificial products deliver may condition the body to anticipate sugar calories that never come, affecting appetite regulation, insulin sensitivity and broader metabolic pathways. However, the authors suggest that how sweeteners affect the gut microbiota and glucose regulation are the most likely drivers of increased diabetes risk.   https://newatlas.com/diet-nutrition/one-drink-diabetes-risk/ XX After months of deliberation, information gathering and public testimony, a state board unanimously agreed Monday that two common medications for type-2 diabetes and other conditions appear to pose an affordability challenge to the state and Marylanders.   The state Prescription Drug Affordability Board approved two resolutions saying that prescription drugs Jardiance and Farxiga likely pose an “an affordability challenge for the state health care system” and the state should look for ways to bring down those costs.   Health care advocates call the long-awaited resolution an “important first step” in the process in bringing down prescription costs for those on the state's health plan.       That milestone has been years in the making. Created in 2019 by the General Assembly, the Prescription Drug Affordability Board was slow to launch due in part to a veto from former Gov. Larry Hogan (R) amid pandemic-induced economic uncertainty in 2020 that delayed the board's formation. The board also cited out-of-pocket costs for consumers and state and local spending on those drugs as indicators that there may be an affordability challenge.   The board will now look at options to address the potential affordability challenge, which could include setting an upper payment limit on those drugs. But it's not clear when the state will see cost savings.   That said, some members of the health care system and the pharmaceutical industry say that policies such as upper payment limits could weaken access to life-saving drugs. Others say that the board has not engaged enough viewpoints from the health care industry. https://marylandmatters.org/2025/07/29/state-board-determines-two-type-2-diabetes-drugs-may-be-unaffordable/   XX One year after it was revealed that Chrissy Teigen and John Legend's son, Miles, was diagnosed with type 1 diabetes, Teigen is revealing how she's making her son feel more included. Teigen first opened up about her 7-year-old son's diagnosis after she and her two oldest kids, Miles and 9-year-old daughter Luna were at the 2024 summer Olympics cheering on Simone Biles. Teigen posted a photo of Miles and Luna holding up a sign. Also visible in the picture was the insulin pump on Miles' arm. Now, Teigen is sharing some insight into how she's making Miles more comfortable with having type 1 diabetes, including giving LeBron James' Barbie doll type 1 diabetes as well. In a video shared on Instagram, Teigen is seen taking the T1D Barbie, removing her insulin pump and gluing the pump onto LeBron James' Barbie. “Turning T1D Barbie into T1D Lebron James for my son,” Teigen captioned the video, revealing James is Miles' hero. 41 million followers https://www.yahoo.com/lifestyle/articles/chrissy-teigen-gives-lebron-james-154608782.html  

In dieser Folge von „Ich bin dann mal erfolgreich“ begrüßen wir zwei Gäste: Dr. Klaus Vitalis Schulz, CEO der Schulz & Sohn GmbH, und Mark Sethe, Geschäftsführer und CFO. Gemeinsam führen sie ein traditionsreiches Unternehmen, das seit 1890 besteht und sich doch immer wieder neu erfindet.Schulz & Sohn steht für Chemie-Erzeugnisse mit Spezialfokus auf Reinigung, Desinfektion und Prozesschemie in unterschiedlichsten Branchen. Ob Großküchen, Industriebetriebe oder medizinische Einrichtungen: Die Produkte des Hauses Schulz stehen für Verlässlichkeit, Wirksamkeit und kompromisslose Qualität.Im Podcast sprechen wir über die Herausforderungen, ein Familienunternehmen in die Zukunft zu führen. Dr. Klaus Vitalis Schulz gibt Einblick in die Geschichte des Hauses, das mittlerweile in vierter Generation geführt wird und das trotzdem nie stehenbleibt. Es geht um unternehmerische Verantwortung, um Marktveränderungen, Regulatorik und die besondere Dynamik eines inhabergeführten Mittelständlers.Mark Sethe ergänzt mit dem Blick des CFOs: Was bedeutet Transformation in einem Unternehmen, das seit über 130 Jahren existiert? Wie gelingt es, Tradition und Innovation zu verbinden? Und wie schafft man es, in Zeiten von Lieferengpässen, Nachhaltigkeitsdruck und Preissensibilität Stabilität zu bewahren?Wir sprechen über Führung im Tandem, über Werte, über Mitarbeiterbindung und über die Frage, wie ein Unternehmen den Spagat meistert zwischen langfristiger Stabilität und der Flexibilität, die ein hochregulierter Markt erfordert.Diese Folge ist ein inspirierender Blick in den Mittelstand und zeigt, wie zwei Führungspersönlichkeiten mit unterschiedlichen Perspektiven ein gemeinsames Ziel verfolgen: Kontinuität schaffen, wo Wandel geschieht.Mark Sethe auf LinkedIn: https://www.linkedin.com/in/marksethe/https://schulzchemie.com

Julie Christeas is the founder and CEO of Tandem Pictures. Her recent films include NUKED, a comedy starring Justin Bartha and Anna Camp, and BLACK BEAR starring Aubrey Plaza, Christopher Abbott, and Sarah Gadon. She also Executive Produced three original, short-form comedy series for NBCU/Peacock, all are slated for release Spring 2025, and produces original short-form content for some of the biggest brands in the world -- Amazon, Chase Bank, Ford Motors, Netflix, Cadillac, and many more. In this interview, we talk about strategies for de-risking film projects, changes in indie filmmaking, how she finds talent and projects, and much more. As a special note, this was part of our new LIVE interview series in partnership with Buzztown, a community for serious screenwriters, where students also participated in this interview. You can learn more or join the waitlist here: https://www.scriptmastermind.com/pr Want more? Steal my first book, INK BY THE BARREL - SECRETS FROM PROLIFIC WRITERS, right now for free. Simply head over to www.brockswinson.com to get your free digital download and audiobook. If you find value in the book, please share it with a friend as we're giving away 100,000 copies this year. It's based on over 400 interviews here at Creative Principles. Enjoy! If you enjoy the podcast, would you please consider leaving a short review on Apple Podcasts? It only takes about 60 seconds, and it really helps convince some of the hard-to-get guests to sit down and have a chat (simply scroll to the bottom of your iTunes Podcast app and click “Write Review"). Enjoy the show!

In this eye-opening episode of Thriving in Tandem, Robert and Kay Lee share the single most common money mistake keeping countless married entrepreneurs from building real wealth: debt. Fresh off the facilitation of a financial stewardship workshop, they dig into how everyday debt—often justified or ignored—is quietly stealing your financial future. But here's the good news: the solution is simpler than you think. Spoiler alert: You have to listen til the end. You'll learn how debt is not just a financial burden, but a barrier to freedom, peace of mind, and legacy-building. Whether it's credit cards, car loans, or payday advances, this conversation explores the hidden costs of “buy now, pay later” culture and how breaking that cycle can unlock wealth potential that most couples never realize. They even run the numbers—showing how just $500/month invested wisely could grow into $1 million over time. If you've ever said, “We don't have enough to invest,” this episode will challenge that belief—and show you exactly how to create margin, eliminate debt, and finally start building long-term wealth together. Practical tips, real-life examples, biblical wisdom, and a strong dose of encouragement await. Want to live a better balanced life and win in marriage AND business at the same time? Purchase our (audio) book Tandem: The married entrepreneurs' guide for greater work-life balance. https://www.thetandembook.com/ Download the 5 Daily Habits to Thrive in Tandem https://marriedentrepreneur.co/5-daily-habits-download  Need some insight into how to balance it all? Schedule a free discovery call. https://marriedentrepreneur.co/lets-talk Debt Repayment Calculator https://www.crown.org/all-resources/debt-snowball-calculator/ Investment/Retirement Calculator https://www.crown.org/all-resources/?cat=economy-investing&type=calculator  Key Takeaways: Debt is the true wealth killer. The average American carries over $20,000 in consumer debt, costing $1,500/month—money that could be building your future. Delayed gratification wins. Saving and paying cash—especially for big-ticket items like cars—can save you thousands and put you on the fast track to financial freedom. Simple strategy, massive results. The debt snowball method helps you eliminate debt faster than you think, freeing up cash for giving, investing, and enjoying life. Building wealth is more doable than you think. Just $500/month invested at 10% can become $1 million over 30 years—yes, really. Freedom from debt brings peace. No matter the economy, having no payments gives you breathing room, confidence, and options.

Want to live a better balanced life and win in marriage AND business at the same time? Purchase our (audio) book Tandem: The married entrepreneurs' guide for greater work-life balance. https://www.thetandembook.com/ Download the 5 Daily Habits to Thrive in Tandem https://marriedentrepreneur.co/5-daily-habits-download  Need some insight into how to balance it all? Schedule a free discovery call. https://marriedentrepreneur.co/lets-talk In this deeply vulnerable and inspiring episode of Thriving in Tandem, we're joined by Krystal Parker, President of the U.S. Christian Chamber of Commerce. Krystal shares her raw journey from corporate executive climbing the ranks of a Fortune 200 oil and gas company to discovering the devastating cost of success when it came at the expense of her marriage and family. What looked like professional triumph on the outside masked a crumbling home life and personal disconnection from what mattered most. As Krystal takes us back to the peak of her corporate climb—fueled by power, ambition, and external validation—she candidly reveals the blind spots that hurt her marriage ending and relationship with her young daughter. But in the aftermath of that breaking point, Krystal discovered what true leadership and intentional living looked like. From restructuring her work-life rhythms to raising up her team, and ultimately placing God and family at the center, her story offers hope and a powerful reminder that redemption is possible. Whether you're in a season of hustle or navigating growing pains in business and marriage, Krystal's testimony is a call to evaluate where your time and heart are going. She shares practical boundaries she and her husband now implement, how she keeps her daughter a priority, and the critical difference between using work as worship instead of worshiping work. This is a must-listen for married entrepreneurs who don't want to succeed in business only to lose what truly matters most. Key Takeaways: Success without alignment can destroy what matters most. Krystal's corporate rise came with sacrifices she didn't fully see until her marriage and family unraveled. You are irreplaceable at work but you not at home. Delegating empowered Krystal's team and freed her to re-engage with her daughter and home life. Boundaries and intention create lasting connection. Krystal and her husband carve out intentional moments—even in busy seasons—to stay united and keep God at the center of their marriage. Chapters 00:00 Introduction to Thriving in Tandem Podcast 02:01 Crystal Parker's Journey in the Oil and Gas Industry 10:11 Challenges of Balancing Career and Family Life 12:00 The Turning Point: Becoming a Solo Parent 18:07 Finding Balance in a New Marriage and Career 23:53 Lessons Learned and Final Thoughts  

This week we break our recorders and record that lo-fi episode all the people want. But seriously we had some technical difficulties so hope our hot takes make it to your ears. Tour talk and Tim does Tandem shopping.  This podcast is also supported by the generous and amazing donors to the Wide Angle Podium Network, and buy Hammerhead cycling! Visit hammerhead.io to check out the Karoo cycling computer, and use code SLOWRIDE at checkout to get a Heart Rate strap for free! Find us, and other fantastic cycling podcasts on the Wide Angle Podium Network, at wideanglepodium.com! Check out the brand new WAP app available in the Apple and Android app stores! You can email us at theslowridepodcast@gmail.com

 My guest this week has personal and professional experience of tandem feeding to share with us. Nicola De Sousa is an infant feeding coach from Jersey, in the Channel Islands. She fed her toddler Mikayla, all through her pregnancy and alongside her infant Diogo.We talk about Nicola's experience of feeding both her children, but also from 28:30 we answer your questions about tandem feeding. For details of the questions covered, please refer to the transcript of this episode.You can follow Nicola on Instagram @infantfeedingcoach.jerseyMy new picture book on how breastfeeding journeys end, The Story of Jessie's Milkies, is available from Amazon here -  The Story of Jessie's Milkies. In the UK, you can also buy it from The Children's Bookshop in Muswell Hill, London. Other book shops and libraries can source a copy from Ingram Spark publishing.You can also get 10% off my books on supporting breastfeeding beyond six months and supporting the transition from breastfeeding at the Jessica Kingsley press website, that's uk.jkp.com using the code MMPE10 at checkout.Follow me on Instagram  @emmapickettibclc or find out more on my website www.emmapickettbreastfeedingsupport.com This podcast is presented by Emma Pickett IBCLC, and produced by Emily Crosby Media.

In this episode, Rebecca and Shaun sit down with Renee Bush, founder of Tandem, a consultancy for interior designers. She's the secret weapon behind the brand and business strategy at powerhouses like Studio McGee. Renee shares her journey from graphic and studio operations into honing a niche helping designers align business structure, brand identity, and marketing.They dive deep into how strategic clarity—knowing who you are, who you're talking to, and what you want—transforms client experience, marketing, pricing, and scale. Renee's wisdom around confident positioning, signature processes and aesthetics, and the importance of a North Star brand makes this a foundational listen for any designer ready to level up.In this episode they discuss:Renee's non-designer path: transitioning from graphic design/studio ops through Studio McGee into founding TandemWhat brand strategy actually means: values, tone, ideal client, mission, emotional deliverablesHow to uncover a designer's unique "North Star" that aligns brand, process, team and marketingThe power of signature processes or aesthetics as a form of positioningWhy confidence—especially in pricing—is the linchpin to attracting the right clientsHow small, strategic changes across branding, social media, press, and referrals generate exponential growthTailoring Instagram and content for your future ideal client without losing your current audienceChoosing between volume of smaller projects vs. fewer high-end ones—and ensuring profitability through smart systemsMentioned:Tandem – with-tandem.comThe Haven List workshop – thehavenlist.com/workshopTandem Instagram – instagram.com/with_tandemTandem Pinterest - pinterest.com/with_tandemEpisode 99 with Ali FaulknerEpisode 149 with Danielle ChiprutOur links:Subscribe and leave a review - Apple PodcastsLike, Comment, & Follow - Hot Young Designers Club InstagramRebecca's InstagramShaun's InstagramFor more information - Check out the websiteBecome a “Loyal Hottie” - Support us on PatreonDesign Resources - Check out our shopMentioned in this episode:Get 50% off your first year + a 14-day free trial with Sortly. https://sortly.com/hydc

In this deeply personal episode, Robert and Kay Lee invite you into their real-time decision-making process as they consider a cross-country move from California to North Carolina. Fresh off a month-long stay in Lake Norman, they share candid reflections on the conversations, emotions, and logistical considerations that come with such a significant transition. From the practical realities of moving and renting to the emotional weight of leaving behind familiarity and friendships, this episode reveals how they approach big decisions as a married couple and entrepreneurial team. Whether you're facing a business pivot, relocation, or other major life decision, you'll gain valuable insights on how to navigate change without unnecessary conflict. Robert and Kay Lee walk through the importance of “baby steps” in decision-making, how to test the waters before diving in, and how differing emotional responses between spouses can actually work together to bring clarity and peace. They also reflect on the value of community, intentionality, and leaning into God's guidance when the future feels uncertain. This episode is not just about moving houses—it's about building a life with intention, staying united through change, and creating space for wise, thoughtful decisions that serve both your marriage and business. Tune in for a behind-the-scenes look at how real-life married entrepreneurs process transition without growing apart. Want to live a better balanced life and win in marriage AND business at the same time? Purchase our (audio) book Tandem: The married entrepreneurs' guide for greater work-life balance. https://www.thetandembook.com/ Download the 5 Daily Habits to Thrive in Tandem https://marriedentrepreneur.co/5-daily-habits-download  Need some insight into how to balance it all? Schedule a free discovery call. https://marriedentrepreneur.co/lets-talk Key Takeaways: Big transitions—whether in life or business—are best navigated in small, intentional steps. Differing emotional responses between spouses are normal and can be leveraged for better communication and mutual understanding. Creating a plan B and “testing the waters” reduces anxiety and sets you up for more confident decision-making. Don't rush into big changes—whether it's a move, business shift, or investment—without first confirming peace and unity as a couple. Community, intentional planning, and faith-driven discernment are key to thriving in tandem through seasons of change. Chapters 00:00 Introduction and Background on the Move 02:52 Exploring Lake Norman and Decision-Making Process 06:09 Testing the Waters: A Month in Lake Norman 08:54 Building Relationships and Community Connections 12:13 Emotional Aspects of Major Life Transitions 15:03 Decision-Making Styles in Relationships 17:56 Taking Baby Steps in Major Changes 20:48 Conclusion and Final Thoughts  

In this eye-opening episode, Dr. Catherine Toon sits down with Robert and Kay Lee Fukui—authors of Tandem: The Married Entrepreneurs’ Guide for Greater Work-Life Balance—to unpack the powerful intersection of faith, business, marriage, and ministry. Together, they explore how to stop sacrificing your family on the altar of achievement and instead walk in divine alignment that honors God, strengthens relationships, and allows business to flourish. From their deeply personal experiences growing up in ministry and entrepreneurial households, the Fukuis share how they overcame generational patterns of imbalance to cultivate a lifestyle of intentional connection, prayerful unity, and clear boundaries. You’ll discover the power of margin over hustle, learn how prayer and unity can bulletproof your marriage, and get practical strategies to harmonize your calling with your relationships. Whether you're navigating the challenges of married life, launching a business, or feeling the pressure to "do it all," this conversation will bring hope, healing, and practical wisdom. It's time to thrive in every area of your life—together. Episode Highlights: * Why sacrificing your family isn’t God’s best—and what to do instead * How to set boundaries and say “no” with confidence and peace * The key to unity in marriage decision-making (and why it matters more than you think) * Practical ways to build margin and maximize time and impact * The surprising divorce statistics among couples who pray together * How faith, intimacy, and purpose unlock success in both ministry and business * The freedom of letting peace lead—plus red flags to watch for in decision-making * Why God’s best is never rushed, pressured, or guilt-laden Website: https://marriedentrepreneur.co/perspectives Book: "Tandem: The married entrepreneurs' guide for greater work-life balance" Click here: https://www.amazon.com/Tandem-married-entrepreneurs-greater-work-life/dp/1953284833 FREE Protect Your Purpose Masterclass: * 3 Keys to Staying Inspired and Thriving in Your Calling to Align with Your God-Given Purpose Watch it now: https://mbl.catherinetoon.com/saveyourspot To support the ministry with tax-deductible donations: https://catherinetoon.com/support/ Please rate, review, share, and subscribe — a little thing that makes a big difference!! Thank you! Resources to Bless You: * "Marked by Love, Revised & Expanded Edition" (#1 Best Seller!): https://bit.ly/3UGeJBI * Get God, Male & Female? on Audible: https://amzn.to/49hzCIM * FREE “How to Hear God” eBook: https://bit.ly/3cTNb49 * FREE Chapter from Marked by Love: https://markedbylovebook.com/free-chapter/ * Explore more resources: https://catherinetoon.com Stay Connected and Share God’s Love! * Facebook: @CatherineToonMD * Instagram: @catherinetoon * Twitter: @CatherineToonMD * YouTube: @CatherineToon, MD

Send us a textTerry M Brown shares how her 3,102-mile journey across America on a tandem bicycle transformed her life and taught her powerful lessons about resilience, presence, and embracing challenges. From escaping an abusive relationship to finding new purpose as an author, her story demonstrates how stepping outside your comfort zone can reveal strengths you never knew you had.• Riding from Oregon to Washington DC on a tandem bicycle with her husband• Overcoming physical and emotional challenges throughout the journey• Learning to "never quit on a bad day" after pushing through difficult conditions• Finding the courage to "do hard things" even when faced with seemingly insurmountable challenges• Accepting that life's journey is rarely a straight line but rather a "tandem journey" filled with unexpected turns• Struggling with and learning to appreciate the importance of staying present• Discovering that success doesn't come from becoming someone else but from uncovering strengths already within• Applying these life lessons beyond the bicycle journey to other challenges like grief and personal growth• Converting the experience into "10 Little Rules for a Blissful-Butted Adventure" with guided journaling questions• Finding healing and purpose through adventure after escaping a 14-year abusive relationshipIf there's something big and bold you've been wanting to do, start taking steps toward it today. Don't keep your dreams on a bucket list—turn them into action plans and begin moving in that direction, because you never know what tomorrow will bring.Follow Teri M. Brown atHer websitehttps://www.terimbrown.com/Her Promoted Bookhttps://www.terimbrown.com/10-little-rules-dba.htmlYouTubehttps://www.youtube.com/channel/UCaQ6p-EOSGd1tEeWijQSl9ATwitterhttps://www.facebook.com/TeriMBrownAuthorPinteresthttps://www.pinterest.com/terimbrownauthor/Instagramhttps://www.instagram.com/terimbrown_authorLinkedinhttps://www.linkedin.com/in/TeriMBrown/TikTokhttps://www.tiktok.com/@terimbrown_authorSupport the showFollow your host atYouTube and Rumble for video contenthttps://www.youtube.com/channel/UCUxk1oJBVw-IAZTqChH70aghttps://rumble.com/c/c-4236474Facebook to receive updateshttps://www.facebook.com/EliasEllusion/Twitter (yes, I refuse to call it X)https://x.com/politicallyht LinkedIn https://www.linkedin.com/in/eliasmarty/

Episode 197: Continuous Glucose MonitoringWritten by William Zeng, MSIII, and Chris Kim, MSIII. University of Southern California.You are listening to Rio Bravo qWeek Podcast, your weekly dose of knowledge brought to you by the Rio Bravo Family Medicine Residency Program from Bakersfield, California, a UCLA-affiliated program sponsored by Clinica Sierra Vista, Let Us Be Your Healthcare Home. This podcast was created for educational purposes only. Visit your primary care provider for additional medical advice.Will: IntroToday we're exploring Continuous Glucose Monitoring, or CGM. We'll break down what CGM is, who benefits, how to access it, options available for our patients, the pros and cons, and a few final reflections on where this technology is heading. Chris, So what is CGM?Chris:Continuous glucose monitoring refers to the use of a small wearable sensor placed just under the skin to track glucose levels in real time throughout the day and night. These sensors measure glucose in the interstitial fluid and transmit readings to a receiver or smartphone at regular intervals, allowing for 24/7 glucose trend tracking. Will:CGM has been shown to improve glycemic control, increase “time in range,” and reduce hypoglycemia. Let's review some evidence.Chris:A 2023 meta-analysis published in Diabetes Technology & Therapeutics reported a mean Hemoglobin A1c reduction of 0.43% across multiple trials. Will:In people with Type 1 diabetes, the IMPACT and DIAMOND studies showed sustained improvement in Hemoglobin A1c and hypoglycemia reduction over 6–12 months. CGM use in insulin-treated Type 2 diabetes patients also resulted in significant benefits, including reduced variability and fewer severe glucose excursions. Chris:Clinically and economically, CGMs help prevent long-term complications such as cardiovascular disease, nephropathy, and retinopathy. Chris, What patients specifically benefit the most from CGM?Will: CGMs are most commonly indicated for people with Type 1 diabetes and for those with Type 2 diabetes who are using intensive insulin regimens—typically defined as multiple daily injections or insulin pump therapy. Chris:And what are the qualifications in order to be covered by insurance?Will:In the United States, Medicare covers CGM as durable medical equipment for qualifying patients, and coverage requires a prescription, documentation of insulin use, and regular follow-up. Most major private insurers—including Blue Cross, Aetna, UnitedHealthcare, Cigna, and Kaiser—follow similar guidelines. Coverage is generally granted for patients with Type 1 diabetes or insulin-requiring Type 2 diabetes who monitor glucose at least four times daily or use an insulin pump. Chris:Some plans require demonstration of hypoglycemia unawareness or frequent glucose variability. For patients not on insulin, OTC CGMs may be an option, but coverage is typically not provided. That said, new FDA decisions are allowing over-the-counter access to CGMs like Abbott's FreeStyle Libre and Dexcom's Stelo, expanding availability for lifestyle or preventive purposes.Will:[There are a lot of products on the market. Which are the main products and how are they different?]Chris:The three main players in the CGM space are Dexcom, Abbott (FreeStyle Libre), and Senseonics (Eversense), each with unique offerings.Let's start with Dexcom. Dexcom G7 is a real-time CGM system approved for both Type 1 and Type 2 diabetes. It combines a sensor and transmitter into one compact wearable patch worn on the abdomen or upper arm for up to 10 days. It updates glucose readings every 5 minutes and connects directly to a smartphone or Apple Watch via Bluetooth. Dexcom also integrates with insulin pumps like Tandem's t:slim and the Omnipod 5. Data can be shared with providers through Dexcom Clarity, which integrates into electronic medical records (EMRs) like Epic. OTC access is not yet available for DEXCOM G7, but a new non-prescription product called Dexcom Stelo is being rolled out in 2025, targeting non-insulin-using Type 2 patients. Dexcom Stelo will also offer 15-day wear, smartphone integration, and factory calibration. The estimated OTC cost for Dexcom Stelo is expected to be around $99 for a 15-day sensor, or about $198/month.Will:$200! Abbott FreeStyle Libre comes in several versions. The Libre 2 offers 14-day wear and requires users to scan the sensor with their smartphone or reader to retrieve a glucose value. It has optional real-time alarms for high and low readings and transmits data to LibreView, which can integrate with most EMRs. Libre 3 is a real-time CGM with 1-minute interval updates, Bluetooth transmission, and a slimmer profile. Libre sensors are widely used in primary care and available OTC for non-insulin users. Libre 2 sensors cost approximately $70–$85 for a 14-day sensor, while Libre 3 is slightly higher, around $85–$100 per sensor—totaling about $140–$200/month out of pocket without insurance.Chris:Senseonics Eversense E3 is the only implantable CGM on the market. It involves a minor in-office procedure to insert the sensor under the skin of the upper arm, which lasts up to 180 days (and a newer version, Eversense 365, lasts up to one year). A removable transmitter worn on top of the skin sends data every 5 minutes to a mobile app and vibrates for alerts. It requires 1–2 calibrations per day using a traditional fingerstick meter. It integrates with Eversense DMS software for physician monitoring. The total cost for Eversense depends on the insertion procedure and insurance, but cash pay for the full 6-month system is estimated at $2,400–$3,000, or about $400–$500/month including follow-up visits.Will:Additional lower-cost CGMs such as the Medtrum A6 TouchCare are available internationally and in select U.S. pilot programs. These devices offer 14-day wear, smartphone syncing, and daily calibration, but are not yet FDA-approved for wide use and lack full EMR integration.Chris:In terms of performance and value, Dexcom G7 offers the most advanced real-time feedback and integration, making it ideal for those on insulin pumps or needing tight control. Will:FreeStyle Libre offers the best affordability and convenience, especially for non-insulin users or those who prefer not to deal with constant alerts. Eversense offers a niche but compelling option for people who want to avoid frequent sensor changes. Chris, [Are there any downsides or risks that patients should be aware of before trying out CGM?]Chris:CGMs are generally safe and well-tolerated, but they do have limitations. Dexcom G7 has a known failure mode where sensors sometimes fail prematurely, often before the full 10-day duration. Some users have reported “signal loss” errors or random disconnections, especially when switching between phone models or operating systems. There are occasional reports of inaccurate highs or lows due to compression during sleep or dehydration. Though the G7 is factory-calibrated, abrupt changes in hydration or blood flow can affect its readings.Will:FreeStyle Libre systems, particularly Libre 2, require the user to scan the sensor to retrieve data unless alerts are enabled. These devices may be affected by vitamin C (ascorbic acid), which can falsely elevate glucose readings, and they do not currently allow for automated insulin delivery integration. Some Libre 2 users have noted adhesive-related rashes or spontaneous detachment. Libre 3, while more advanced, still may lose Bluetooth connection intermittently, particularly if the phone is out of range or the app is not running in the background.Chris:Senseonics Eversense carries procedural risks due to its implantable nature. Minor scarring or infection at the insertion site has been reported. The transmitter must be worn during waking hours to provide alerts, and users report anxiety over losing the transmitter since data logging is interrupted without it. Calibration is still required, which adds to daily tasks. Additionally, the sensor does not communicate with insulin pumps or closed-loop systems.Will:All CGMs can cause mild skin irritation from adhesive, particularly in users with sensitive skin. Alert fatigue is another consideration, as frequent low- or high-glucose warnings may cause stress or lead users to silence notifications entirely. Finally, relying solely on CGM without periodic fingerstick confirmation in symptomatic scenarios can be a risk, especially during rapid glucose changes.Chris:Conclusion[***] Continuous glucose monitors have reshaped the way we manage diabetes, offering unprecedented insight into glucose trends, diet responses, and insulin timing. While CGMs are not flawless, the technology continues to evolve. Will: If your patient is on insulin or struggling with glucose variability, consider whether CGM is right for your patient. For those not using insulin, consider newer OTC options like FreeStyle Libre or Dexcom Stelo, which offer accessible entry points without the need for prescriptions. As AI integration, longer sensor life, and non-invasive monitoring enter the market, CGM will only become more useful.Dr Arreaza: Personal experience with CGMs. I do not have diabetes, but I have a strong family history of diabetes (including father, 2 grandmas, and about 15 uncles, aunts, and cousins.)I wanted to try it so I could teach my patients about CGM. My first experience was with Freestyle Libre 2: Pros: Painless placement, easy to use, scanning with phone was easier than fingersticks.Cons: Required some assembling to be placed, mild discomfort at night, and nighttime alarms.Dexcom G7:Pros: No need for scanning, feels more stable in your armCons: High readings (had to calibrate for a more accurate reading)Even without trying, every night you go to bed a little wiser. Thanks for listening to Rio Bravo qWeek Podcast. We want to hear from you, send us an email at RioBravoqWeek@clinicasierravista.org, or visit our website riobravofmrp.org/qweek. See you next week! _____________________References:Theme song, Works All The Time by Dominik Schwarzer, YouTube ID: CUBDNERZU8HXUHBS, purchased from https://www.premiumbeat.com/.

Der Weltradsportverband UCI will die Technikregeln ändern. Das wird Auswirkungen auf viele Rennräder haben. Wir sprechen über Details, Hintergründe und Fragezeichen angesichts der neuen Regeln. (00:00:00) Intro (00:00:38) Danksagung für die Unterstützer*innen (00:03:44) Das heutige Thema: Neue Regeln für Rennräder in Wettkämpfen (00:05:12) Neue UCI Equipment-Regeln (00:07:25) Sicherheitsaspekte (00:10:40) Lenkerbreite (00:22:59) Innenweite von Gabeln und Rahmen (00:25:42) Aero-Helm-Verbot (00:26:58) Begrenzung der Entfaltung (00:32:47) Bedeutung der neuen Regeln für Hersteller (00:38:30) Historische Entscheidungen der UCI (00:43:05) Interessenabwägung durch die UCI (00:49:48) Fazit (00:51:57) Outro (00:53:57) MGMT – Time To Pretend Coverfoto: Bernard Papon / Pool / AFP Hier könnt ihr uns bei Steady unterstützen: https://steadyhq.com/de/antritt/about Hier entlang geht's zu den Links unserer Werbepartner: https://detektor.fm/werbepartner/antritt >> Artikel zum Nachlesen: https://detektor.fm/gesellschaft/antritt-uci-kuendigt-neue-technikregeln-fuer-rennraeder-an

Der Weltradsportverband UCI will die Technikregeln ändern. Das wird Auswirkungen auf viele Rennräder haben. Wir sprechen über Details, Hintergründe und Fragezeichen angesichts der neuen Regeln. (00:00:00) Intro (00:00:38) Danksagung für die Unterstützer*innen (00:03:44) Das heutige Thema: Neue Regeln für Rennräder in Wettkämpfen (00:05:12) Neue UCI Equipment-Regeln (00:07:25) Sicherheitsaspekte (00:10:40) Lenkerbreite (00:22:59) Innenweite von Gabeln und Rahmen (00:25:42) Aero-Helm-Verbot (00:26:58) Begrenzung der Entfaltung (00:32:47) Bedeutung der neuen Regeln für Hersteller (00:38:30) Historische Entscheidungen der UCI (00:43:05) Interessenabwägung durch die UCI (00:49:48) Fazit (00:51:57) Outro (00:53:57) MGMT – Time To Pretend Coverfoto: Bernard Papon / Pool / AFP Hier könnt ihr uns bei Steady unterstützen: https://steadyhq.com/de/antritt/about Hier entlang geht's zu den Links unserer Werbepartner: https://detektor.fm/werbepartner/antritt >> Artikel zum Nachlesen: https://detektor.fm/gesellschaft/antritt-uci-kuendigt-neue-technikregeln-fuer-rennraeder-an

Femi Abebefe & Jared Smith wrap up their NFL Head Coach-QB Tandem draft. To learn more about listener data and our privacy practices visit: https://www.audacyinc.com/privacy-policy Learn more about your ad choices. Visit https://podcastchoices.com/adchoices

9-10am Hour 4 - Joe DiBiase talks with Kyle Bailey about the Carolina Panthers and if they'll start to see some sort of success after past years of failure. Joe also talks about the importance of this year's goaltending tandem for the Buffalo Sabres and how much pressure is on Devon Levi to become an NHL goaltender.

In the latest episode of the What the FinTech? podcast, we're joined by Suavek Zajac, chief technology officer at Tandem Bank, who discusses how the bank implements technology to support customers in adopting more environmentally sustainable lifestyles. Suavek joins FinTech Futures reporter Cameron Emanuel-Burns to explore how Tandem balances delivering personalised, immediate services while maintaining its environmental commitments, along with covering the bank's recent work involving AI and large language models. The episode also uncovers Suavek's perspective on emerging technologies that could transform sustainable banking practices, as well as his accomplishments as CTO, including the development of the Green Hub and Connect platform. And finally, Suavek reveals which fintech buzzword deserves freedom or confinement in our Fintech Jail!

SiriusXM NHL Radio and Daily Faceoff Analyst Carter Hutton joined OverDrive to discuss the headlines around the NHL, the tandem of Anthony Stolarz and Joseph Woll, the NHL CBA guidelines for goaltenders, Gavin McKenna committing to Penn State and the impact to the NCAA, Stuart Skinner's ceiling with the Oilers, the importance of a goaltending coach, Stolarz's contract number and more.

Brian and Marty talk about the Sabres goaltenders headed into the 2025-26 season.

What will the Sabres goaltending tandem look like in 2025? full 914 Mon, 07 Jul 2025 17:24:38 +0000 PibLCo2HNzFZTQJQsB5gylhsa3593IbQ sports Sabres Live sports What will the Sabres goaltending tandem look like in 2025? No radio station in the USA talks more hockey than WGR Sports Radio 550 and no radio station talks more Buffalo Sabres and NHL hockey better than us. Heard daily from 12PM-1PM on WGR and simulcast on MSG TV, Sabres Live goes deep into the corners everyday, breaking down the play and the players of every Sabres game. Plus, we take listeners around the NHL getting the inside scoop on all the top stories. 2024 © 2021 Audacy, Inc. Sports False https://player.amperwavepodcasting

Luke Grenfell-Shaw is a remarkable endurance athlete, and cancer advocate whose story reads like a masterclass in resilience. Diagnosed with stage 4 sarcoma at just 24, he refused to let the label “incurable” define him. Instead, he coined the term “CanLiver”.He's cycled 30,000 km from Bristol to Beijing on a tandem bike, inviting hundreds of others, including fellow CanLivers, to join him along the way. He's since become a professional trail runner for Brooks, and he casually ran an 80-minute half marathon during chemotherapy.https://www.alifeintandemfilm.com/https://www.instagram.com/lukegshaw/ XMILES UK - Listeners now receive 10% of their order value back as store credit via the link below.https://xmiles.avln.me/c/RiwxnARvfHeRRunderwear - Use code TEATRAILS15 for 15% off your orderhttps://runderwear.avln.me/c/GPVNMgMfYfLPSHOKZ - Use code TEA102025 to receive £10 off.https://uk.shokz.com?sca_ref=7394994.MfsDQZBAeLQihiPrecision Fuel & Hydration https://visit.pfandh.com/3GKxHjUPrecision Fuel & Hydration Planner https://visit.pfandh.com/3RuP25zHarrier - Use code TEA10 for 10% off. https://harrierrunfree.co.uk/Fenixlight Limited - Use code T&T5 for 5% off your order.https://www.fenixlight.co.uk/Protein Rebel - Use code Tea15 for 15% off your first order. https://proteinrebel.com/Centurion Running - Use code TEAANDTRAILS10 to receive 10% off *Excluding Sale Items.https://centurionrunning.com/GOODR - Use code GOTEAANDTRAILS to reveive 10% off your order.https://goodr.avln.me/c/VLEmsAIZCDtmLIFE JACKET SKIN PROTECTION - Use code GOTYOURBACK for 10% off your first order.https://lifejacketskin.com/PRIMUS UK - Use code TT-PRIMUS-20 for 20& off.https://primusuk.avln.me/c/kBWmOJaEiByDContent may contain affiliate links which can help support and grow this channel at no extra cost to you. Thanks for your continued support!Brew with the Coaches - CLICK HEREKeeping Dry & Staying Warm - https://amzn.to/42JCexqFix Your Feet - https://amzn.to/3FE4nf0Running Challenges by Keri Wallace - https://amzn.to/3KGdU7eROAR - https://amzn.to/3WU7xB2NEXT LEVEL - https://amzn.to/3Hu15LrUltra Trails - https://www.ultratrails.co.uk/Greener Miles - https://greenermilesrunning.co.uk/Hannah Walsh - https://www.hannahwalsh.co.uk/Punk Panther - https://www.punkpanther.co.uk/Pen Llyn Ultra - https://penllyn.niftyentries.com

Mitte Juni hat in Leipzig das erste „Antritt“-Treffen stattgefunden. Wir haben mit unseren Unterstützerinnen und Unterstützern gesprochen und ziehen ein fröhliches Fazit. (00:00:00) Begrüßung – Es ist heiß! (00:04:35) Antritt-Treffen (00:06:46) Die Ausfahrt (00:11:09) Johannes aus dem Taunus (00:13:42) Matthias aus Sauerlach (00:16:08) Andreas aus Duisburg (00:18:01) Niklas aus Regensburg (00:20:08) Bernd aus der Nähe von Stuttgart (00:21:59) Christian aus Leipzig (00:24:11) Alex aus Berlin (00:25:37) Sandra und Jochen aus Gemmingen (00:27:47) Marco aus Dresden (00:29:31) Mikio aus Berlin (00:32:50) Manuel aus Leipzig (00:36:24) Gefühle zum Hörer*innentreffen (00:42:40) Ausblick (00:53:06) Dendemann – Gedanken, gut Hier könnt ihr den beim Antritt-Treffen aufgezeichneten Live-Podcast mit Hanka Kupfernagel hören: Wie wird man so oft Weltmeisterin, Hanka Kupfernagel? Hier könnt ihr uns bei Steady unterstützen: https://steadyhq.com/de/antritt/about Hier entlang geht's zu den Links unserer Werbepartner: https://detektor.fm/werbepartner/antritt >> Artikel zum Nachlesen: https://detektor.fm/gesellschaft/antritt-rueckblick-auf-das-erste-antritt-treffen

Mitte Juni hat in Leipzig das erste „Antritt“-Treffen stattgefunden. Wir haben mit unseren Unterstützerinnen und Unterstützern gesprochen und ziehen ein fröhliches Fazit. (00:00:00) Begrüßung – Es ist heiß! (00:04:35) Antritt-Treffen (00:06:46) Die Ausfahrt (00:11:09) Johannes aus dem Taunus (00:13:42) Matthias aus Sauerlach (00:16:08) Andreas aus Duisburg (00:18:01) Niklas aus Regensburg (00:20:08) Bernd aus der Nähe von Stuttgart (00:21:59) Christian aus Leipzig (00:24:11) Alex aus Berlin (00:25:37) Sandra und Jochen aus Gemmingen (00:27:47) Marco aus Dresden (00:29:31) Mikio aus Berlin (00:32:50) Manuel aus Leipzig (00:36:24) Gefühle zum Hörer*innentreffen (00:42:40) Ausblick (00:53:06) Dendemann – Gedanken, gut Hier könnt ihr den beim Antritt-Treffen aufgezeichneten Live-Podcast mit Hanka Kupfernagel hören: Wie wird man so oft Weltmeisterin, Hanka Kupfernagel? Hier könnt ihr uns bei Steady unterstützen: https://steadyhq.com/de/antritt/about Hier entlang geht's zu den Links unserer Werbepartner: https://detektor.fm/werbepartner/antritt >> Artikel zum Nachlesen: https://detektor.fm/gesellschaft/antritt-rueckblick-auf-das-erste-antritt-treffen

In this episode, we welcome Dr. Justin and Dr. Courtney Mosley, a powerhouse chiropractic couple and owners of Music City Health Center, one of the largest natural health clinics in Middle Tennessee. They share their journey of building a business and marriage together, from their serendipitous meeting to navigating the challenges of working side by side. The Mosleys reveal how they learned to honor each other's strengths, set clear business boundaries, and scale their practice to achieve both professional success and personal balance. Dr. Justin, known as the Mindset Doctor, also takes us through his near-death experience and how it reshaped his purpose, leading him to impact lives beyond the clinic through speaking, coaching, and masterminds. Meanwhile, Dr. Courtney discusses the importance of prioritizing health, setting boundaries, and creating a sustainable business model that allows them to serve their community without sacrificing their well-being. They provide invaluable insights for married entrepreneurs on building a thriving business without burnout, leading by example, and making faith-driven decisions. Podcast: The Mindset Doctor https://podcasts.apple.com/us/podcast/the-mindset-doctor-podcast/id1676852153  Follow Dr. Justin on Instagram at @drjustinmosley and Dr. Courtney at @doccourtney Watch Dr. Justin's TED Talk on overcoming fear of public speaking: https://youtu.be/aImrjNPrh30?feature=shared Need chiropractic care in Nashville? Visit https://www.musiccityhealthcenter.com/ Key Takeaways: The power of aligning your business and marriage vision before starting a venture together. How learning from other entrepreneurial couples helped them navigate working as spouses. The importance of setting business boundaries to prevent burnout and maintain work-life balance. How Dr. Justin's near-death experience led to a mission shift and greater impact. The significance of honoring each other's strengths and hiring strategically to scale a business. Why faith and intuition should play a role in major business and life decisions. Bio Dr. Justin and Dr. Courtney Moseley are the owners of Music City Health Center, one of the largest natural health clinics in Middle Tennessee. Dr. Justin Moseley, known as The Mindset Doctor, is a 2-time TEDx speaker, international keynote speaker, and host of The Mindset Doctor Podcast. After surviving a near-death accident in 2018, he shifted his mission from transforming lives in his clinic to inspiring audiences worldwide. Dr. Justin empowers others to unlock their full potential, create next-level success, and leave a lasting legacy. Dr. Courtney is on a mission to empower women to reclaim their energy, balance their hormones, and rediscover the joy of living.  Want to live a better balanced life and win in marriage AND business at the same time? Purchase our (audio) book Tandem: The married entrepreneurs' guide for greater work-life balance. https://www.thetandembook.com/ Download the 5 Daily Habits to Thrive in Tandem https://marriedentrepreneur.co/5-daily-habits-download  Need some insight into how to balance it all? Schedule a free discovery call. https://marriedentrepreneur.co/lets-talk

Face à la série "HPI" sur TF1, au magazine "Envoyé spécial" sur France 2 et à l'émission "J'en connais un rayon" sur M6, c'est France 3 qui se hisse en tête des audiences de ce jeudi soir grâce à la série "Tandem". Distribué par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

ITB's Eagles beat reporter Andrew DiCecco gives his insights and observations from covering the Eagles on a daily basis. #philadelphiaeagles #eagles #flyeaglesfly #nicksirianni #jalenhurts #tannermckee #kylemccord #saquonbarkley #ajbrown In this positional preview podcast series, he starts by looking at quarterback.

Romelu Lukaku werd dit seizoen voor de tweede keer kampioen in de Italiaanse Serie A. Zijn eerste titel met Napoli. Nu de kampioenenviering achter de rug is, maakt hij uitgebreid tijd om met Maarten Vangramberen te praten. Over de transfer van Kevin De Bruyne naar Napoli, de Rode Duivels en Anderlecht. Lukaku geeft ons een inkijk in zijn toekomst waarin nog veel gevoetbald zal worden, want de topschutter van de Rode Duivels wil nog zeker doorgaan tot zijn 40ste.

Face à une rediffusion d'un épisode de "Tandem", c'est TF1 qui arrive en tête des audiences de ce jeudi soir grâce à une rediffusion d'un épisode de la série “HPI”.Distribué par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

Replica del 20 GIUGNO 2025Ogni pomeriggio dalle 16 alle 18, Danny Morandi e Michael Casanova, vi fanno compagnia con le loro pazzie, la loro allegria e la loro complicità accompagnandovi a casa con il loro tandem!Il venerdì pedaleranno con voi un'ora in più (dalle 15 alle 18)

Replica del 18 GIUGNO 2025Ogni pomeriggio dalle 16 alle 18, Danny Morandi e Michael Casanova, vi fanno compagnia con le loro pazzie, la loro allegria e la loro complicità accompagnandovi a casa con il loro tandem!Il venerdì pedaleranno con voi un'ora in più (dalle 15 alle 18)

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: what is adaptive biobehavioral control for AID systems? Omnipod 5 launches iOS app with Dexcom G7 compatability and a comic book(?!), Tandem and Abbott announce new partnership, Katie Bone is back on American Ninja Warrior, and more! Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom   Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links: Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX The American Diabetes Association Scientific Sessions kicks off in a week – we expect as always to get a lot of information! I'm not covering in person this year, but I'll bring you any big announcements. And we'll do a wrap up In the News the following week. -- XX UVA with something new.. technology that allows an artificial pancreas system to adapt to users' changing needs – and lets users adjust the settings – beyond what's commercially available now. They're calling this “adaptive biobehavioral control,” the technology helps fine-tune UVA's artificial pancreas every two weeks, giving users a virtual tool to test different ways to manage their blood sugar using their own data. In a six-month study, participants using the technology spent more time in a healthy blood-sugar range, rising from 72% to 77%, and saw a small but meaningful drop in their average blood-sugar levels. While automated insulin delivery systems help users better manage Type 1 diabetes, adaptive biobehavioral control technology is designed to improve blood-sugar control during the day, when fluctuations occur more frequently due to meals and physical activity. This new technology uses “digital twins,” computer models simulating how a person's body processes sugar. The models help the artificial pancreas keep up with changes in the user's body and habits and give users a way to interact with the system. For example, users can try different settings, like how much insulin is released overnight, using the simulation before applying them in real life. https://news.virginia.edu/content/uvas-artificial-pancreas-uses-digital-twin-tech-improve-diabetes-control XX Five years later after COVID-19 his the US, a new study shows that there is a connection with type 1 diabetes triggers. This is  new research from the University of Utah published in the journal ImmunoInformatics.   With T1D in particular, a COVID infection appears to trigger the immune system of certain people who have a prior susceptibility to the condition to subsequently develop T1D symptoms, the new study suggests.   University of Utah researchers hypothesize that COVID is leading to T1D diagnoses in a roundabout way as the virus presents the body with “molecular mimics,” or fragments of COVID proteins that bear an uncanny resemblance to those beta cell antigens.   When a person is infected with COVID, the immune system not only attacks fragments of the viral protein but also attacks fragments of beta cell antigens because they look so similar and get mistaken for each other, explains lead study author Julio Facelli, Ph.D., a distinguished professor of biomedical informatics at University of Utah Health in Salt Lake City. That means that in people who are already predisposed to T1D, there may be a simultaneous autoimmune reaction involving the destruction of healthy beta cells, spurring the onset of type 1 diabetes. Both 2022 and 2024 research indicates that there has been a significant increase in new onset type 1 diabetes following the start of the COVID pandemic. It's difficult to estimate just how many cases may have been triggered by COVID because numerous viruses, including rotavirus, measles, mumps, and rubella, can spark an autoimmune response that activates T1D, according to the 2022 research published in Immunology & Cell Biology.   Again, it's important to note that researchers don't believe a COVID infection is causing diabetes, but rather, triggering it, in the same way certain environmental factors are believed to trigger immune-mediated conditions like Crohn's and psoriasis. “   https://www.healthcentral.com/news/type-1-diabetes/how-covid-might-trigger-t1d XX Insulet announces the Omnipod® 5 App for iPhone is now compatible with the Dexcom G7. Eric Benjamin, Insulet Executive Vice President, Chief Product and Customer Experience Officer. “With the addition of the Dexcom G7 sensor to the Omnipod 5 App for iPhone, our U.S. customers have more choice with fewer devices to keep track of, making it easier than ever to manage their diabetes.” The Omnipod 5 App with Dexcom G7 and Dexcom G6 compatibility is now available for download on the Apple App Store. Switching to a new Omnipod 5 device will require you to go through First Time Setup again. Insulin delivery history from previous Pods will be lost when you switch to your new device and adaptivity will start over. Use this guide and video to help transfer your settings: Omnipod also announced a collaboration with Marvel.. on an original comic to celebrate representation for the diabetes community and empower people with diabetes to unleash their inner hero. “Dyasonic: Sound of Strength” features Omnya, who was recently diagnosed with type 1 diabetes, struggles with her management, and is prescribed an insulin pump. Omnya learns that when her glucose levels are in range she can take on anything, and anyone, and transforms into the comic's hero, Dyasonic! The hope is that readers will be able to see themselves overcoming these same challenges and break mental barriers to adopting technology with the potential for improved outcomes and quality of life. D'Spayre is a Marvel villain who preys on victims who are in despair, using their fear to strengthen himself—akin to the negative emotions that can come with diabetes. Insulet remains dedicated to advancing diabetes technology and improving the lives of people with diabetes. For more information, please visit https://www.omnipod.com/innovation. XX Tandem is the latest partner for Abbot's future Glucose-Ketone Sensor. New agreement to develop and commercialize integrated diabetes solutions that combine Abbott's future dual glucose-ketone sensor with Tandem's innovative insulin delivery systems to provide more options for people to manage their diabetes. The Abbott sensor, currently under development, will combine glucose and ketone sensing technology that aims to help people living with diabetes detect early ketone rise to avoid life-threatening diabetic ketoacidosis. Sequel Med Tech is also partnering with Abbott on this, as part of the twist pump, launching later this year. https://www.stocktitan.net/news/TNDM/tandem-diabetes-care-announces-agreement-with-abbott-for-integration-xl1vug3c0axy.html   XX New guidelines for the management of type 2 diabetes and prediabetes include tools clinicians can use to help patients stick to lifestyle interventions.   A panel of practitioners working in lifestyle medicine, including primary care physicians, cardiologists, endocrinologists, sleep experts, dietitians, and exercise medicine specialists, laid out six areas clinicians should help patients manage. These include sleep and stress, nutrition, physical activity, tobacco and alcohol, and social connection. The guidelines, released on June 10 by the American College of Lifestyle Medicine (ACLM), largely mirror lifestyle guidelines by the American Diabetes Association (ADA) but add specifics about how clinicians can help patients achieve their goals. Each patient should still receive tailored counseling, which may include medication   https://www.medscape.com/viewarticle/new-guidelines-shift-diabetes-care-toward-behavior-2025a1000fht XX Microplastics from a widely used biodegradable material can enter the metabolic cycle of bacteria and cells in the gut after being ingested, a new study has found. Researchers in China and the United States said the microplastics – from polylactic acid – were found to alter the gut metabolism and damage the gut barrier of mice.   They said this could potentially contribute to conditions like inflammatory bowel disease and diabetes. In recent years, microplastics have been found in human lungs, kidneys, blood, placenta and breast milk.   https://www.scmp.com/news/china/science/article/3313412/microplastics-biodegradable-material-may-be-linked-diabetes-study-finds XX ​​Over 19,000 cases of Dr Pepper Zero Sugar are being recalled after the cans were found to contain full-sugar soda, the U.S. Food and Drug Administration announced. The voluntary recall, initiated May 23, affects 12-pack and 24-pack cases of the 12-ounce aluminum cans that are labeled “Dr Pepper Zero Sugar.” Despite the label, the drinks inside contain the same amount of sugar found in regular Dr Pepper — about 39 grams per can — posing a health risk for people with diabetes or anyone needing to limit sugar intake. On Thursday, June 5, the FDA officially classified the recall as Class II, meaning the product “may cause temporary or medically reversible adverse health consequences." DR PEPPER ZERO SUGAR - 12 OZ, 12 PK DR PEPPER ZERO SUGAR - 12 OZ, 12 PK.  Amazon Consumers can identify the recalled cases by the product code, which is listed as  XXXXRS05165, and the "best by" date of Feb. 16, 2026   No other Dr Pepper products or batches of Dr Pepper Zero Sugar are part of the recall. https://people.com/dr-pepper-recall-sugar-found-in-zero-sugar-cans-11750981     XX A step forward for a device that uses breath to gather information about blood sugar. It's called Isaac, the company is PreEvnt, you wear it on a lanyard and breathe into it. The breathalyzer technology was developed in collaboration with the Integrated Nanosystems Development Institute at IU Indianapolis, and was inspired by diabetes alert dogs. "Our lab was able to successfully identify the specific molecules in breath that correlate with hypoglycemia, which is the 'scent' that diabetic alert dogs can detect," said Mangilal Agarwal, director of the Integrated Nanosystems Development Institute and a professor in the IU Luddy School of Informatics, Computing and Engineering at IU Indianapolis. Agarwal's lab is partnering with the IU School of Medicine to test and validate the effectiveness of the device in individuals with diabetes—an important next step on the path to wider commercialization. https://medicalxpress.com/news/2025-06-breathalyzer-device-diabetes.html#google_vignette XX Katie Bone is back on American Ninja Warrior! The youngest ever American Ninja Warrior Women's National winner, she injured her knee at Olympic Climbing Trials in 2023. This week, she was back on the show. She says: Katie Bone: It was incredible. I've not been able to compete for a few years, so getting to come back and hit a buzzer on my first chance back on the course felt really, really incredible; Very rewarding after everything I had to go through to get back there. XX  

The Vancouver real estate market sits at a crossroads, with buyers, developers, and realtors torn between taking action or waiting for conditions to improve. Industry veteran and founder of Tandem Strategies, Sunny Hahm, sits down with Adam & Matt this week to unpack this pivotal moment. From what product types are actually moving to how pricing strategies have evolved, Sunny shares insights from the front lines—highlighting why clear messaging is now more critical than costly marketing campaigns. The conversation dives into townhome success stories, shifting buyer psychology, and the importance of reading sub-market signals rather than relying on broad headlines. Is this fight or flight mentality holding back Vancouver's recovery? What drives better decisions when uncertainty is the only constant? And why might hesitation prove more expensive than taking action in today's market? A must-listen for anyone navigating the current market.

The one and only Pete Prisco joins J.P. Shadrick and Bucky Brooks for the last episode of Huddle Up during the offseason. The crew demands more respect for Jaguars star wide receiver Brian Thomas Jr. and ponders the passing threat with the addition of 2025 second overall pick Travis Hunter. Later, they list off more intriguing storylines that've developed during OTAs and minicamp. All this and more on today's show presented by Fields Auto Group.See omnystudio.com/listener for privacy information.

Hey there! Dive into a world of endless laughs as the Liquid Late Nights crew unravels the hilarious mishaps of trying to break up with a persistent pool guy. Ever heard of someone ghosting, but in real life? Let's just say, it's not as easy as it seems! Oh, and if you love chaotic adventures, from Twin Peaks competitions to the mind-boggling traffic in Tampa, we've got stories that'll keep you entertained from start to finish. So pull up a chair, grab your drink, and enjoy the colorful banter!

How does someone who has been through multiple bear and bull markets in crypto, cope with such a volatile industry? Keep Building.  In this “Live from Links” episode, Caitlin Barnett, Director of Regulation & Compliance at Chainalysis) reconnects with her former Gemini co-worker, Ira Auerbach (Head of Tandem, Offchain Labs) as they go deep on the scalability and innovation challenges and successes on the Ethereum blockchain.  Ira shares the initiatives at NASDAQ and Gemini that bridged traditional finance products to the crypto market and how his focus has shifted at Offchain Labs, where they are fostering blockchain innovation, solving complex computational challenges and emphasizing stablecoins' impact on market dynamics. A great episode for founders, investors and compliance folks in the crypto industry.  Minute-by-minute episode breakdown 2 | Lessons from many crypto bull and bear markets 4 | Focus on institutional solutions and stablecoins 6 | Offchain Labs and Arbitrum improve scalability and usability on Ethereum 8 | Blockchain gaming, decentralized sequencers and fully homomorphic encryption (FHE) 10 | Tandem's partner studio and venture capital Approach 12 | Current crypto investment landscape 14 | Camelot and the industry's shift to DeFi after centralized collapses 16 |Future of investing in blockchain and AI 18 | Thoughts on stablecoin infrastructure players in the industry Related resources Check out more resources provided by Chainalysis that perfectly complement this episode of the Public Key. Website: Offchain Labs: Scaling Ethereum Without Compromise Blog: Bringing Interoperability to Arbitrum and Ethereum Announcement: Tandem by OCL Invests in Camelot, the Largest Native DEX on Arbitrum Blog: OFAC Sanctions Funnull Technology Inc. for Supporting Pig Butchering Scams Blog: Bitcoin Strategic Reserves: Behind the Changing Architecture of Sovereign Finance Blog: AI-Powered Crypto Scams: How Artificial Intelligence is Being Used for Fraud YouTube: Chainalysis YouTube page Twitter: Chainalysis Twitter: Building trust in blockchain Speakers on today's episode Caitlin Barnett *host* (Director of Regulation & Compliance, Chainalysis) Ira Auerbach (Head of Tandem, Offchain Labs) This website may contain links to third-party sites that are not under the control of Chainalysis, Inc. or its affiliates (collectively “Chainalysis”). Access to such information does not imply association with, endorsement of, approval of, or recommendation by Chainalysis of the site or its operators, and Chainalysis is not responsible for the products, services, or other content hosted therein. Our podcasts are for informational purposes only, and are not intended to provide legal, tax, financial, or investment advice. Listeners should consult their own advisors before making these types of decisions. Chainalysis has no responsibility or liability for any decision made or any other acts or omissions in connection with your use of this material. Chainalysis does not guarantee or warrant the accuracy, completeness, timeliness, suitability or validity of the information in any particular podcast and will not be responsible for any claim attributable to errors, omissions, or other inaccuracies of any part of such material.  Unless stated otherwise, reference to any specific product or entity does not constitute an endorsement or recommendation by Chainalysis. The views expressed by guests are their own and their appearance on the program does not imply an endorsement of them or any entity they represent. Views and opinions expressed by Chainalysis employees are those of the employees and do not necessarily reflect the views of the company. 

Seth and Sean dive into some clips of Kamari Lassiter and Jalen Pitre talking about how amazing Derek Stingley is and assess if Lassiter and Sting could be a top CB tandem in the league this year.

Seth and Sean discuss if they'd do a hypothetical trade to bring Kevin Durant to the Rockets, assess if Kamari and Sting could be a top CB tandem this year, and react to Saquon Barkley saying he might just retire out of nowhere at some point.

Oranje start de campagne naar het WK2026 in Finland. Daarbij staat het geraamte van de ploeg met ervaren Internationals. Daar waar Oranje nog moet starten aan de reeks is een aantal landen al zeker van deelname. In de AD Voetbalpodcast bespreken Etienne Verhoeff en Sjoerd Mossou niet alleen Indonesië en de kansen, maar ook de verbazing over China en WK’s. De interesse van Wolfsburg in Simonis komt ook aan bod, net als wat laatste transfers en de ode aan het amateurvoetbal van de KNVB. Beluister de hele AD Voetbalpodcast nu via AD.nl, de AD App of jouw favoriete podcastplatform.Wil je de Ode aan het amateurvoetbal zien? Bekijk hem dan hier.Support the show: https://krant.nl/See omnystudio.com/listener for privacy information.

The Investment Team is back with our 20th episode of Tandem Talk—this time with something completely different! Episode 20 marks five years of conversations around the table. If you've tuned in since the beginning, we thank you for your listenership and for bearing with us as we figured this whole podcast thing out (no more hour-long episodes!). In this episode, we dive into our mission here at Tandem – helping to keep clients invested through all markets, by providing a more consistent, more repeatable, and less volatile investment experience.

In this episode of Thriving in Tandem, Robert and Kay Lee Fukui break down five essential strategies to grow your business without sacrificing your marriage. From setting clear boundaries between work and home to increasing profit margins, they discuss how to work smarter, not harder, so you can scale your business while staying connected to your spouse. They also share personal insights from their time at Lake Norman, reflecting on how intentional rest fuels creativity and productivity. The couple emphasizes the importance of managing work hours, prioritizing high-impact tasks, and delegating effectively to reclaim time for what matters most. They explain how improving profit margins allows you to reduce stress and avoid the endless hustle, making room for both business growth and a thriving relationship. Finally, they highlight the often-overlooked key to success: listening to your spouse's perspective, which can provide valuable insights and prevent costly blind spots in your business. Want to live a better balanced life and win in marriage AND business at the same time? Purchase our (audio) book Tandem: The married entrepreneurs' guide for greater work-life balance. https://www.thetandembook.com/ Download the 5 Daily Habits to Thrive in Tandem https://marriedentrepreneur.co/5-daily-habits-download  Need some insight into how to balance it all? Schedule a free discovery call. https://marriedentrepreneur.co/lets-talk Key Takeaways: ✅ Set Clear Boundaries – Establish firm work-life boundaries to protect quality time with your spouse and family. ✅ Manage Your Work Hours – More hours don't always mean more productivity; focus on efficiency over effort. ✅ Prioritize High-Value Tasks – Spend time on revenue-generating activities and delegate or automate busywork. ✅ Increase Profit Margins – Raise prices strategically and cut inefficiencies to work less while earning more. ✅ Listen to Your Spouse – Their outside perspective can reveal blind spots and help you make better business decisions.

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: Tandem's new infusion set is approved, Dexcom G7 compatibility with the Omnipod 5 iPhone app announced, Sernova cell-pouch moves forward, GLP-1 meds for T1D, and more! Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom   Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links: Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX Tandem gets FDA clearance for a new infusion set. The company shared in an SEC filing that its Capillary Biomedical (CapBio) subsidiary won clearance for its SteadiSet Infusion Set. SteadiSet features an integrated inserter with a hidden needle designed for one-handed insertion. It received clearance to deliver insulin for up to three days of use. However, Tandem plans to submit a separate request to extend the indicated use time to up to seven days. It doesn't expect to begin commercial activities for SteadiSet until after it receives clearance for the extended use time. Many of us have been following this since Tandem acquired CapBio back in 2022.. it's been pretty hush hush – CapBio has never accepted my requests for interviews, so I'm excited to see this approval, mostly because my son really really needs it! https://www.drugdeliverybusiness.com/tandem-capbio-fda-clearance-insulin-infusion-set/ XX   Insulet just announced via an email to health care providers that Dexcom G7 compatibility with the Omnipod 5 iPhone app will be released IN THE COMING WEEKS! Great news for people with #t1d and XX Sernova announces positive interim data from its ongoing Phase 1/2 clinical trial in patients with T1D. this is their Cell Pouch Bio-hybrid Organ as a functional cure for type 1 diabetes (T1D), today Interim data from 12 patients with transplanted human donor islet cells show patients achieving insulin independence, islet cell engraftment in Cell Pouch, islet function, islet survival, improved glycemic control, improved patient reported quality of life (QOL) and improved awareness of hypoglycemia and increased sensitivity to severe hypoglycemic symptoms. Improvement in patient outcomes was correlated with a cumulative increase in the quantity of transplanted islets. Based on these findings, the study is on track to meet its primary and secondary endpoints, and the confirmatory Cohort C is expected to initiate in H2 2025.   Clinical trials with iPSC islet-like clusters from Sernova's partner, Evotec, are anticipated to begin in 2026 after completion of Cohort C of the ongoing trial. These interim findings, with 8 of 12 patients achieving insulin independence so far, support the thesis that Sernova's high volume ten channel Cell Pouch, used in Cohort B, plus an optimised immune suppression regimen, has the potential to achieve insulin independence, without portal vein transplant, in our planned clinical trial with Evotec's high quality iPSC islet-like clusters. Measured HbA1c (a blood test that shows the average blood sugar levels over the past 2-3 months) in patients with Cell Pouch alone, showed that 9 of 12 patients had a reduced value within the American Diabetes Association (ADA) recommended range of

This week on Diabetes Connections, the Eversense CGM gets its first pump partner. This is the implantable CGM sensor – it now lasts for a year.. and it will soon connect with the twist.. a brand new insulin pump. I'm joined by Brian Hansen, the president of CGM at Ascenia, that's the company that distributes Eversense, to talk about how this will work, what's changed for eversense, besides the much longer wear, and what the future holds. This was a wide ranging conversation and a fun one. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. My guest Brian Hansen was appointed the this president of CGM in early 2024. Before that, among other jobs,  he chief commercial office at Tandem. We have followed Eversense for a long time, including talking to people who have worn it for a long time – I'll link up our previous episodes in the show notes. Our previous episodes about Eversense here Join us at an upcoming Moms' Night Out event! Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom  Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.

Who would you want on your Tour de France tandem? Would Pogi and Almeida beat Vingegaard and Jorgenson? These are other important questions answered on this episode of Spin Cycle. Caley, Kit, and Dane run through Liège, Remco Evenepoel's very bad day, Ben Healy's breath of fresh air, and Demi Vollering's disappointing spring. Plus, Chris Froome retirement news and an appreciation for good kit, from Kit of course.